
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E483F38AEEFFF30583F3001DAA24E8.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369923/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cancer">
<meta name="citation_title" content="Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience">
<meta name="citation_author" content="Roberto Cairoli">
<meta name="citation_author_institution" content="Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy">
<meta name="citation_author_institution" content="Department of Medicine and Surgery, University of Milano Bicocca, Milano, Italy">
<meta name="citation_author" content="Lorenzo Del Castello">
<meta name="citation_author_institution" content="Department of Clinical Research and Innovation, Bicocca Bioinformatics Biostatistics and Bioimaging Center B4, School of Medicine and Surgery, University of Milano‐Bicocca, Monza, Italy, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy">
<meta name="citation_author" content="Silvia Imbergamo">
<meta name="citation_author_institution" content="Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy">
<meta name="citation_author" content="Elisabetta Pierdomenico">
<meta name="citation_author_institution" content="Hematology Unit, Istituto Oncologico Veneto IRCCS, Castelfranco Veneto, Province of Treviso, Italy">
<meta name="citation_author" content="Cristina Papayannidis">
<meta name="citation_author_institution" content="Istituto di Ematologia “Seragnoli”, IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Bologna, Italy">
<meta name="citation_author" content="Erika Borlenghi">
<meta name="citation_author_institution" content="Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy">
<meta name="citation_author" content="Calogero Vetro">
<meta name="citation_author_institution" content="Hematology Unit, Azienda Ospedaliera dell&#x27;Alto Adige, Bolzano, Italy">
<meta name="citation_author" content="Patrizia Chiusolo">
<meta name="citation_author_institution" content="Hematology Unit, Università Cattolica Del Sacro Cuore, Rome, Italy">
<meta name="citation_author" content="Monica Fumagalli">
<meta name="citation_author_institution" content="Division of Hematology and Bone Marrow Transplant Unit, Ospedale San Gerardo, Monza, Province of Monza and Brianza, Italy">
<meta name="citation_author" content="Clara Minotti">
<meta name="citation_author_institution" content="Department of Translational and Precision Medicine, Sapienza University, Rome, Italy">
<meta name="citation_author" content="Francesco Marchesi">
<meta name="citation_author_institution" content="Hematology and Stem Cell Transplant Unit, IRCCS‐Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy">
<meta name="citation_author" content="Massimo Bernardi">
<meta name="citation_author_institution" content="Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy">
<meta name="citation_author" content="Pellegrino Musto">
<meta name="citation_author_institution" content="Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy">
<meta name="citation_author" content="Nicola Fracchiolla">
<meta name="citation_author_institution" content="SC Ematologia, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy">
<meta name="citation_author" content="Anna Candoni">
<meta name="citation_author_institution" content="Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia Italy, Modena, Italy">
<meta name="citation_author" content="Monia Lunghi">
<meta name="citation_author_institution" content="Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy">
<meta name="citation_author" content="Maurizio Musso">
<meta name="citation_author_institution" content="Hematology Unit, Clinica La Maddalena Division of Onco‐Hematology and Stem Cell Transplantation, Palermo, Italy">
<meta name="citation_author" content="Fabio Guolo">
<meta name="citation_author_institution" content="Hematology Unit, Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy">
<meta name="citation_author" content="Donato Mannina">
<meta name="citation_author_institution" content="Hematology Unit, Azienda Ospedali Riuniti Papardo Piemonte, Messina, Italy">
<meta name="citation_author" content="Albana Lico">
<meta name="citation_author_institution" content="Hematology Unit, San Bortolo Hospital, Vicenza, Italy">
<meta name="citation_author" content="Anna Maria Scattolin">
<meta name="citation_author_institution" content="Hematology Unit, Ospedale Dell&#x27;Angelo, Mestre, Venice, Italy">
<meta name="citation_author" content="Monica Crugnola">
<meta name="citation_author_institution" content="Hematology Unit, University of Parma, Parma, Italy">
<meta name="citation_author" content="Sara Galimberti">
<meta name="citation_author_institution" content="Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy">
<meta name="citation_author" content="Gianpaolo Nadali">
<meta name="citation_author_institution" content="Hematology Unit, Azienda Ospedaliera di Verona, Verona, Italy">
<meta name="citation_author" content="Mauro Turrini">
<meta name="citation_author_institution" content="Section of Hematology, Valduce Hospital, Como, Italy">
<meta name="citation_author" content="Patrizia Zappasodi">
<meta name="citation_author_institution" content="Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy">
<meta name="citation_author" content="Elisabetta Todisco">
<meta name="citation_author_institution" content="Division of Hematology, ASST Valleolona, Ospedale di Busto Arsizio, Busto Arsizio, Province of Varese, Italy">
<meta name="citation_author" content="Claudia Basilico">
<meta name="citation_author_institution" content="Division of Hematology, ASST Settelaghi, Ospedale di Circolo, Varese, Italy">
<meta name="citation_author" content="Giovanni Grillo">
<meta name="citation_author_institution" content="Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy">
<meta name="citation_author" content="Valentina Mancini">
<meta name="citation_author_institution" content="Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy">
<meta name="citation_author" content="Marta Riva">
<meta name="citation_author_institution" content="Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy">
<meta name="citation_author" content="Davide Paolo Bernasconi">
<meta name="citation_author_institution" content="Department of Clinical Research and Innovation, Bicocca Bioinformatics Biostatistics and Bioimaging Center B4, School of Medicine and Surgery, University of Milano‐Bicocca, Monza, Italy, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy">
<meta name="citation_author" content="Rosa Greco">
<meta name="citation_author_institution" content="Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="131">
<meta name="citation_issue" content="17">
<meta name="citation_firstpage" content="e70055">
<meta name="citation_doi" content="10.1002/cncr.70055">
<meta name="citation_pmid" content="40839405">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369923/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369923/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369923/pdf/CNCR-131-e70055.pdf">
<meta name="description" content="This real‐world study evaluated the clinical effectiveness of gilteritinib in 205 patients with relapsed or refractory (R/R) FLT3‐mutated acute myeloid leukemia (AML) enrolled in the Italian expanded access since January 2018. Of the 205 patients, ...">
<meta name="og:title" content="Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="This real‐world study evaluated the clinical effectiveness of gilteritinib in 205 patients with relapsed or refractory (R/R) FLT3‐mutated acute myeloid leukemia (AML) enrolled in the Italian expanded access since January 2018. Of the 205 patients, ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369923/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12369923">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/cncr.70055"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/CNCR-131-e70055.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12369923%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12369923/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12369923/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369923/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/cncr.70055" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cancer</button></div>. 2025 Aug 21;131(17):e70055. doi: <a href="https://doi.org/10.1002/cncr.70055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/cncr.70055</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cancer%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cancer%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cairoli%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Roberto Cairoli</span></a><div hidden="hidden" id="id1">
<h3>
<span class="name western">Roberto Cairoli</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Medicine and Surgery, University of Milano Bicocca, Milano, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cairoli%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Roberto Cairoli</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Del%20Castello%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Lorenzo Del Castello</span></a><div hidden="hidden" id="id2">
<h3>
<span class="name western">Lorenzo Del Castello</span>, <span class="degrees">MS</span>
</h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Department of Clinical Research and Innovation, Bicocca Bioinformatics Biostatistics and Bioimaging Center B4, School of Medicine and Surgery, University of Milano‐Bicocca, Monza, Italy, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Del%20Castello%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lorenzo Del Castello</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Imbergamo%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Silvia Imbergamo</span></a><div hidden="hidden" id="id3">
<h3>
<span class="name western">Silvia Imbergamo</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Imbergamo%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Silvia Imbergamo</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pierdomenico%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Elisabetta Pierdomenico</span></a><div hidden="hidden" id="id4">
<h3>
<span class="name western">Elisabetta Pierdomenico</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>5</sup>
</sup>Hematology Unit, Istituto Oncologico Veneto IRCCS, Castelfranco Veneto, Province of Treviso, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pierdomenico%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Elisabetta Pierdomenico</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Papayannidis%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Cristina Papayannidis</span></a><div hidden="hidden" id="id5">
<h3>
<span class="name western">Cristina Papayannidis</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>6</sup>
</sup>Istituto di Ematologia “Seragnoli”, IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Bologna, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Papayannidis%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Cristina Papayannidis</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Borlenghi%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Erika Borlenghi</span></a><div hidden="hidden" id="id6">
<h3>
<span class="name western">Erika Borlenghi</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>7</sup>
</sup>Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Borlenghi%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Erika Borlenghi</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vetro%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Calogero Vetro</span></a><div hidden="hidden" id="id7">
<h3>
<span class="name western">Calogero Vetro</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>8</sup>
</sup>Hematology Unit, Azienda Ospedaliera dell'Alto Adige, Bolzano, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vetro%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Calogero Vetro</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chiusolo%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Patrizia Chiusolo</span></a><div hidden="hidden" id="id8">
<h3>
<span class="name western">Patrizia Chiusolo</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>9</sup>
</sup>Hematology Unit, Università Cattolica Del Sacro Cuore, Rome, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chiusolo%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Patrizia Chiusolo</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fumagalli%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Monica Fumagalli</span></a><div hidden="hidden" id="id9">
<h3>
<span class="name western">Monica Fumagalli</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>10</sup>
</sup>Division of Hematology and Bone Marrow Transplant Unit, Ospedale San Gerardo, Monza, Province of Monza and Brianza, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fumagalli%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Monica Fumagalli</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Minotti%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Clara Minotti</span></a><div hidden="hidden" id="id10">
<h3>
<span class="name western">Clara Minotti</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>11</sup>
</sup>Department of Translational and Precision Medicine, Sapienza University, Rome, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Minotti%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Clara Minotti</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Marchesi%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Francesco Marchesi</span></a><div hidden="hidden" id="id11">
<h3>
<span class="name western">Francesco Marchesi</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>12</sup>
</sup>Hematology and Stem Cell Transplant Unit, IRCCS‐Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Marchesi%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Francesco Marchesi</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bernardi%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Massimo Bernardi</span></a><div hidden="hidden" id="id12">
<h3>
<span class="name western">Massimo Bernardi</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>13</sup>
</sup>Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bernardi%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Massimo Bernardi</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Musto%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Pellegrino Musto</span></a><div hidden="hidden" id="id13">
<h3>
<span class="name western">Pellegrino Musto</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>14</sup>
</sup>Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Musto%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Pellegrino Musto</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fracchiolla%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Nicola Fracchiolla</span></a><div hidden="hidden" id="id14">
<h3>
<span class="name western">Nicola Fracchiolla</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>15</sup>
</sup>SC Ematologia, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fracchiolla%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Nicola Fracchiolla</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Candoni%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Anna Candoni</span></a><div hidden="hidden" id="id15">
<h3>
<span class="name western">Anna Candoni</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>16</sup>
</sup>Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia Italy, Modena, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Candoni%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Anna Candoni</span></a>
</div>
</div>
<sup>16</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lunghi%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Monia Lunghi</span></a><div hidden="hidden" id="id16">
<h3>
<span class="name western">Monia Lunghi</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>17</sup>
</sup>Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lunghi%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Monia Lunghi</span></a>
</div>
</div>
<sup>17</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Musso%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Maurizio Musso</span></a><div hidden="hidden" id="id17">
<h3>
<span class="name western">Maurizio Musso</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>18</sup>
</sup>Hematology Unit, Clinica La Maddalena Division of Onco‐Hematology and Stem Cell Transplantation, Palermo, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Musso%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Maurizio Musso</span></a>
</div>
</div>
<sup>18</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guolo%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Fabio Guolo</span></a><div hidden="hidden" id="id18">
<h3>
<span class="name western">Fabio Guolo</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>19</sup>
</sup>Hematology Unit, Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guolo%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fabio Guolo</span></a>
</div>
</div>
<sup>19</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mannina%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Donato Mannina</span></a><div hidden="hidden" id="id19">
<h3>
<span class="name western">Donato Mannina</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>20</sup>
</sup>Hematology Unit, Azienda Ospedali Riuniti Papardo Piemonte, Messina, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mannina%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Donato Mannina</span></a>
</div>
</div>
<sup>20</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lico%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Albana Lico</span></a><div hidden="hidden" id="id20">
<h3>
<span class="name western">Albana Lico</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>21</sup>
</sup>Hematology Unit, San Bortolo Hospital, Vicenza, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lico%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Albana Lico</span></a>
</div>
</div>
<sup>21</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Scattolin%20AM%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Anna Maria Scattolin</span></a><div hidden="hidden" id="id21">
<h3>
<span class="name western">Anna Maria Scattolin</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>22</sup>
</sup>Hematology Unit, Ospedale Dell'Angelo, Mestre, Venice, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Scattolin%20AM%22%5BAuthor%5D" class="usa-link"><span class="name western">Anna Maria Scattolin</span></a>
</div>
</div>
<sup>22</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Crugnola%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id22"><span class="name western">Monica Crugnola</span></a><div hidden="hidden" id="id22">
<h3>
<span class="name western">Monica Crugnola</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>23</sup>
</sup>Hematology Unit, University of Parma, Parma, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Crugnola%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Monica Crugnola</span></a>
</div>
</div>
<sup>23</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Galimberti%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id23"><span class="name western">Sara Galimberti</span></a><div hidden="hidden" id="id23">
<h3>
<span class="name western">Sara Galimberti</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>24</sup>
</sup>Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Galimberti%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sara Galimberti</span></a>
</div>
</div>
<sup>24</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nadali%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id24"><span class="name western">Gianpaolo Nadali</span></a><div hidden="hidden" id="id24">
<h3>
<span class="name western">Gianpaolo Nadali</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>25</sup>
</sup>Hematology Unit, Azienda Ospedaliera di Verona, Verona, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nadali%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Gianpaolo Nadali</span></a>
</div>
</div>
<sup>25</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Turrini%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id25"><span class="name western">Mauro Turrini</span></a><div hidden="hidden" id="id25">
<h3>
<span class="name western">Mauro Turrini</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>26</sup>
</sup>Section of Hematology, Valduce Hospital, Como, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Turrini%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mauro Turrini</span></a>
</div>
</div>
<sup>26</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zappasodi%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id26"><span class="name western">Patrizia Zappasodi</span></a><div hidden="hidden" id="id26">
<h3>
<span class="name western">Patrizia Zappasodi</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>27</sup>
</sup>Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zappasodi%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Patrizia Zappasodi</span></a>
</div>
</div>
<sup>27</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Todisco%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id27"><span class="name western">Elisabetta Todisco</span></a><div hidden="hidden" id="id27">
<h3>
<span class="name western">Elisabetta Todisco</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>28</sup>
</sup>Division of Hematology, ASST Valleolona, Ospedale di Busto Arsizio, Busto Arsizio, Province of Varese, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Todisco%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Elisabetta Todisco</span></a>
</div>
</div>
<sup>28</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Basilico%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id28"><span class="name western">Claudia Basilico</span></a><div hidden="hidden" id="id28">
<h3>
<span class="name western">Claudia Basilico</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>29</sup>
</sup>Division of Hematology, ASST Settelaghi, Ospedale di Circolo, Varese, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Basilico%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Claudia Basilico</span></a>
</div>
</div>
<sup>29</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Grillo%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id29"><span class="name western">Giovanni Grillo</span></a><div hidden="hidden" id="id29">
<h3>
<span class="name western">Giovanni Grillo</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Grillo%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Giovanni Grillo</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mancini%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id30"><span class="name western">Valentina Mancini</span></a><div hidden="hidden" id="id30">
<h3>
<span class="name western">Valentina Mancini</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mancini%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Valentina Mancini</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Riva%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id31"><span class="name western">Marta Riva</span></a><div hidden="hidden" id="id31">
<h3>
<span class="name western">Marta Riva</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Riva%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marta Riva</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bernasconi%20DP%22%5BAuthor%5D" class="usa-link" aria-describedby="id32"><span class="name western">Davide Paolo Bernasconi</span></a><div hidden="hidden" id="id32">
<h3>
<span class="name western">Davide Paolo Bernasconi</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Department of Clinical Research and Innovation, Bicocca Bioinformatics Biostatistics and Bioimaging Center B4, School of Medicine and Surgery, University of Milano‐Bicocca, Monza, Italy, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bernasconi%20DP%22%5BAuthor%5D" class="usa-link"><span class="name western">Davide Paolo Bernasconi</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Greco%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id33"><span class="name western">Rosa Greco</span></a><div hidden="hidden" id="id33">
<h3>
<span class="name western">Rosa Greco</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Greco%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Rosa Greco</span></a>
</div>
</div>
<sup>1</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="cncr70055-aff-0001">
<sup>
<sup>1</sup>
</sup>Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy</div>
<div id="cncr70055-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of Medicine and Surgery, University of Milano Bicocca, Milano, Italy</div>
<div id="cncr70055-aff-0003">
<sup>
<sup>3</sup>
</sup>Department of Clinical Research and Innovation, Bicocca Bioinformatics Biostatistics and Bioimaging Center B4, School of Medicine and Surgery, University of Milano‐Bicocca, Monza, Italy, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy</div>
<div id="cncr70055-aff-0004">
<sup>
<sup>4</sup>
</sup>Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy</div>
<div id="cncr70055-aff-0005">
<sup>
<sup>5</sup>
</sup>Hematology Unit, Istituto Oncologico Veneto IRCCS, Castelfranco Veneto, Province of Treviso, Italy</div>
<div id="cncr70055-aff-0006">
<sup>
<sup>6</sup>
</sup>Istituto di Ematologia “Seragnoli”, IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Bologna, Italy</div>
<div id="cncr70055-aff-0007">
<sup>
<sup>7</sup>
</sup>Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy</div>
<div id="cncr70055-aff-0008">
<sup>
<sup>8</sup>
</sup>Hematology Unit, Azienda Ospedaliera dell'Alto Adige, Bolzano, Italy</div>
<div id="cncr70055-aff-0009">
<sup>
<sup>9</sup>
</sup>Hematology Unit, Università Cattolica Del Sacro Cuore, Rome, Italy</div>
<div id="cncr70055-aff-0010">
<sup>
<sup>10</sup>
</sup>Division of Hematology and Bone Marrow Transplant Unit, Ospedale San Gerardo, Monza, Province of Monza and Brianza, Italy</div>
<div id="cncr70055-aff-0011">
<sup>
<sup>11</sup>
</sup>Department of Translational and Precision Medicine, Sapienza University, Rome, Italy</div>
<div id="cncr70055-aff-0012">
<sup>
<sup>12</sup>
</sup>Hematology and Stem Cell Transplant Unit, IRCCS‐Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy</div>
<div id="cncr70055-aff-0013">
<sup>
<sup>13</sup>
</sup>Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy</div>
<div id="cncr70055-aff-0014">
<sup>
<sup>14</sup>
</sup>Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy</div>
<div id="cncr70055-aff-0015">
<sup>
<sup>15</sup>
</sup>SC Ematologia, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy</div>
<div id="cncr70055-aff-0016">
<sup>
<sup>16</sup>
</sup>Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia Italy, Modena, Italy</div>
<div id="cncr70055-aff-0017">
<sup>
<sup>17</sup>
</sup>Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy</div>
<div id="cncr70055-aff-0018">
<sup>
<sup>18</sup>
</sup>Hematology Unit, Clinica La Maddalena Division of Onco‐Hematology and Stem Cell Transplantation, Palermo, Italy</div>
<div id="cncr70055-aff-0019">
<sup>
<sup>19</sup>
</sup>Hematology Unit, Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy</div>
<div id="cncr70055-aff-0020">
<sup>
<sup>20</sup>
</sup>Hematology Unit, Azienda Ospedali Riuniti Papardo Piemonte, Messina, Italy</div>
<div id="cncr70055-aff-0021">
<sup>
<sup>21</sup>
</sup>Hematology Unit, San Bortolo Hospital, Vicenza, Italy</div>
<div id="cncr70055-aff-0022">
<sup>
<sup>22</sup>
</sup>Hematology Unit, Ospedale Dell'Angelo, Mestre, Venice, Italy</div>
<div id="cncr70055-aff-0023">
<sup>
<sup>23</sup>
</sup>Hematology Unit, University of Parma, Parma, Italy</div>
<div id="cncr70055-aff-0024">
<sup>
<sup>24</sup>
</sup>Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy</div>
<div id="cncr70055-aff-0025">
<sup>
<sup>25</sup>
</sup>Hematology Unit, Azienda Ospedaliera di Verona, Verona, Italy</div>
<div id="cncr70055-aff-0026">
<sup>
<sup>26</sup>
</sup>Section of Hematology, Valduce Hospital, Como, Italy</div>
<div id="cncr70055-aff-0027">
<sup>
<sup>27</sup>
</sup>Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy</div>
<div id="cncr70055-aff-0028">
<sup>
<sup>28</sup>
</sup>Division of Hematology, ASST Valleolona, Ospedale di Busto Arsizio, Busto Arsizio, Province of Varese, Italy</div>
<div id="cncr70055-aff-0029">
<sup>
<sup>29</sup>
</sup>Division of Hematology, ASST Settelaghi, Ospedale di Circolo, Varese, Italy</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence</strong>
, 
Roberto Cairoli, Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20162, Milano, Italy. 
Email: <span>roberto.cairoli@ospedaleniguarda.it</span>

</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 17; Received 2025 May 6; Accepted 2025 Jul 24; Issue date 2025 Sep 1.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Cancer</em> published by Wiley Periodicals LLC on behalf of American Cancer Society.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12369923  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40839405/" class="usa-link">40839405</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="cncr70055-sec-0001"><h3 class="pmc_sec_title">Background and Methods</h3>
<p>This real‐world study evaluated the clinical effectiveness of gilteritinib in 205 patients with relapsed or refractory (R/R) FLT3‐mutated acute myeloid leukemia (AML) enrolled in the Italian expanded access since January 2018.</p></section><section id="cncr70055-sec-0002"><h3 class="pmc_sec_title">Results</h3>
<p>Of the 205 patients, 124 (60.5%) received gilteritinib as a bridging therapy to allogeneic stem cell transplantation (allo‐SCT), achieving complete remission in 52.4% (<em>n</em> = 65). The median overall survival (OS) for the entire cohort was 11.0 months, with estimated OS rates of 46.8% at 1 year and 28.5% at 3 years. Sixty patients (48% of those bridged) underwent allo‐SCT after a median of 3.7 months on gilteritinib, achieving posttransplant OS rates of 65.2% at 1 year and 56.1% at 3 years. The acquisition of FLT3 mutations at relapse and the presence of TP53 co‐mutations were significantly associated with inferior outcomes. Among 46 patients (22.4%) who relapsed after allo‐SCT, gilteritinib treatment yielded an overall response rate (ORR) of 54.3%, a median OS of 11.1 months, and 1‐ and 3‐year OS rates of 49.5% and 15.5%, respectively. Additionally, 35 patients (17.1%) previously treated with nonintensive chemotherapy received gilteritinib until disease progression or intolerance, achieving an ORR of 11.4%, a median OS of 5.9 months, and a 1‐year OS rate of 29.0%.</p></section><section id="cncr70055-sec-0003"><h3 class="pmc_sec_title">Conclusions</h3>
<p>These real‐world data confirm that clinical outcomes achieved with gilteritinib in patients with R/R FLT3‐mutated AML are consistent with those observed in pivotal clinical trials. Notably, approximately half of the transplant‐eligible patients were successfully bridged to allo‐SCT and demonstrated encouraging long‐term survival.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> acute myeloid leukemia, FLT3, gilteritinib, tyrosine kinase inhibitor, real‐world</p></section></section><section class="abstract" id="abstract2"><h2>Short abstract</h2>
<p>This real‐world study evaluated 205 patients with relapsed or refractory <em>FLT3‐</em>mutated acute myeloid leukemia treated with gilteritinib in the Italian Expanded Access Program. Outcomes were consistent with pivotal trials, with nearly half of transplant‐eligible patients successfully bridged to allogeneic stem cell transplantation and showing encouraging long‐term survival, whereas efficacy was limited in those previously treated with nonintensive chemotherapy.</p></section><section id="cncr70055-sec-0010"><h2 class="pmc_sec_title">INTRODUCTION</h2>
<p>Acute myeloid leukemia (AML) is a major contributor to cancer‐related mortality, ranking as the eleventh leading cause of cancer death worldwide, with a 15% increase in incidence over the past 3 decades.<a href="#cncr70055-bib-0001" class="usa-link" aria-describedby="cncr70055-bib-0001">
<sup>1</sup>
</a>
</p>
<p>Leukemogenesis is driven by the accumulation of genetic abnormalities—including somatic mutations, epigenetic alterations in immature myeloid cells, and chromosomal aberrations—that drive clonal proliferation.<a href="#cncr70055-bib-0002" class="usa-link" aria-describedby="cncr70055-bib-0002">
<sup>2</sup>
</a>
</p>
<p>Molecular characterization has become central to AML diagnosis, classification, and treatment. Current guidelines emphasize genetic profiling over traditional morphology,<a href="#cncr70055-bib-0001" class="usa-link" aria-describedby="cncr70055-bib-0001">
<sup>1</sup>
</a> with recurrent mutations such as <em>FLT3</em>, <em>NPM1</em>, and <em>TP53</em> guiding prognostic stratification and therapeutic decisions.<a href="#cncr70055-bib-0003" class="usa-link" aria-describedby="cncr70055-bib-0003">
<sup>3</sup>
</a> These molecular insights have led to the development of targeted agents, among which <em>FLT3</em> inhibitors represent a key therapeutic advance.<a href="#cncr70055-bib-0004" class="usa-link" aria-describedby="cncr70055-bib-0004">
<sup>4</sup>
</a>
</p>
<p>
<em>FLT3</em> mutations—particularly internal tandem duplications (ITD) and tyrosine kinase domain (TKD) point mutations like D835—lead to constitutive receptor activation and leukemic transformation.<a href="#cncr70055-bib-0005" class="usa-link" aria-describedby="cncr70055-bib-0005">
<sup>5</sup>
</a>
</p>
<p>Gilteritinib, a type I <em>FLT3</em> inhibitor, targets both ITD and TKD mutations by binding the ATP‐binding site and interacting with the F691 gatekeeper residue, as confirmed by computational modeling. In vitro assays show potent inhibition of <em>FLT3</em>, <em>ALK</em>, and <em>AXL</em>, including all tested D835 variants.<a href="#cncr70055-bib-0006" class="usa-link" aria-describedby="cncr70055-bib-0006">
<sup>6</sup>
</a>
</p>
<p>Gilteritinib was first evaluated in the phase 1 Chrysalis trial, where patients with relapsed/refractory (R/R) <em>FLT3</em>‐mutated AML—primarily with ITD mutations—achieved a composite complete response (CRc) rate of 41% at doses ≥80 mg. Responses occurred even in patients with dual mutations or prior resistance to sorafenib or quizartinib, and 19% proceeded to allogeneic hematopoietic stem cell transplantation (HSCT)<a href="#cncr70055-bib-0007" class="usa-link" aria-describedby="cncr70055-bib-0007">
<sup>7</sup>
</a>
</p>
<p>The phase 3 Admiral trial subsequently enrolled 371 patients with FLT3‐mutated AML in first relapse or refractory to initial induction therapy. Participants were randomized 2:1 or to single‐agent gilteritinib or investigator‐selected salvage chemotherapy (SC), including intensive and low‐intensity regimens. Gilteritinib demonstrated superior efficacy, with higher CRc rates (54% vs. 22%), longer median overall survival (9.3 vs. 5.6 months; hazard ratio [HR], 0.64; <em>p</em> = .001), and a greater proportion undergoing HSCT (26% vs. 15%).<a href="#cncr70055-bib-0008" class="usa-link" aria-describedby="cncr70055-bib-0008">
<sup>8</sup>
</a> Common adverse events included cytopenias, infections, and elevated liver enzymes. Common adverse events included cytopenias, infections, and elevated liver transaminases.<a href="#cncr70055-bib-0008" class="usa-link" aria-describedby="cncr70055-bib-0008">
<sup>8</sup>
</a>
</p>
<p>Following a 21% complete remission (CR)/complete remission with partial hematological recovery (CRh) rate in interim analysis, gilteritinib received initial approval in September 2018 from the Japanese Ministry of Health, Labour, and Welfare for the treatment of <em>FLT3‐</em>mutated R/R AML,<a href="#cncr70055-bib-0009" class="usa-link" aria-describedby="cncr70055-bib-0009">
<sup>9</sup>
</a> followed by regulatory approvals from the US Food and Drug Administration<a href="#cncr70055-bib-0010" class="usa-link" aria-describedby="cncr70055-bib-0010">
<sup>10</sup>
</a> and the European Medicines Agency in October 2019.<a href="#cncr70055-bib-0011" class="usa-link" aria-describedby="cncr70055-bib-0011">
<sup>11</sup>
</a> In compliance with regulatory guidelines, post‐marketing studies and expanded access programs (EAPs) were initiated globally to evaluate gilteritinib’s safety, tolerability, and effectiveness in real‐world settings.<a href="#cncr70055-bib-0009" class="usa-link" aria-describedby="cncr70055-bib-0009">
<sup>9</sup>
</a>, <a href="#cncr70055-bib-0012" class="usa-link" aria-describedby="cncr70055-bib-0012">
<sup>12</sup>
</a>, <a href="#cncr70055-bib-0013" class="usa-link" aria-describedby="cncr70055-bib-0013">
<sup>13</sup>
</a>, <a href="#cncr70055-bib-0014" class="usa-link" aria-describedby="cncr70055-bib-0014">
<sup>14</sup>
</a>, <a href="#cncr70055-bib-0015" class="usa-link" aria-describedby="cncr70055-bib-0015">
<sup>15</sup>
</a>, <a href="#cncr70055-bib-0016" class="usa-link" aria-describedby="cncr70055-bib-0016">
<sup>16</sup>
</a>, <a href="#cncr70055-bib-0017" class="usa-link" aria-describedby="cncr70055-bib-0017">
<sup>17</sup>
</a> In Italy, gilteritinib has been available through an EAP since January 2018. This retrospective and prospective observational study reports clinical outcomes from Italian centers participating in the national EAP.</p>
<p>The primary aim is to assess the real‐world clinical effectiveness of gilteritinib in patients with relapsed or refractory <em>FLT3</em>‐mutated AML under routine clinical practice.</p></section><section id="cncr70055-sec-0020"><h2 class="pmc_sec_title">MATERIALS AND METHODS</h2>
<section id="cncr70055-sec-0030"><h3 class="pmc_sec_title">Study design</h3>
<p>This multicenter, retro‐prospective, observational study (REL‐AML 002/2021) was conducted across 27 Italian hospitals involved in the gilteritinib EAP beginning in January 2018. Data acquisition was finalized, and the last follow‐up was completed in October 2024, marking the formal conclusion of the study. The study was conducted under the auspices of the Rete Ematologica Lombarda (REL) network. Gilteritinib was administered as monotherapy in accordance with the approved therapeutic indication. Each enrolled patient was followed from the initiation of gilteritinib treatment until death or last contact. For the prospective component, follow‐up continued for 12 months after the enrollment of the last patient.</p></section><section id="cncr70055-sec-0040"><h3 class="pmc_sec_title">Study population</h3>
<p>Patients eligible for inclusion in the study were required to be over 18 years of age, have a diagnosis of relapsed or refractory acute myeloid leukemia (AML R/R) with an <em>FLT3</em> mutation confirmed on retesting, and have received gilteritinib monotherapy within the EAP. Before any data collection, all patients provided written informed consent. Ethical approval for the study was granted by CET3 Lombardia. The study was conducted in accordance with all relevant local regulations and the ethical principles outlined in the Declaration of Helsinki.</p>
<p>Within the relapsed and refractory cohort, patients were further categorized into two groups: patients eligible for allogeneic transplantation and patients ineligible for transplantation. Additionally, we separately analyzed the subgroup of patients who experienced relapse following transplantation and, for patients with refractory disease, we investigated the potential impact of refractoriness after one versus multiple courses of intensive chemotherapy.</p></section><section id="cncr70055-sec-0050"><h3 class="pmc_sec_title">Statistical analysis</h3>
<section id="cncr70055-sec-0060"><h4 class="pmc_sec_title">End points and response criteria</h4>
<p>The primary end point of the study was overall survival (OS), defined as the time from the initiation of gilteritinib to death from any cause. In the subgroup of patients eligible for allogeneic stem cell transplantation (allo‐SCT), we analyzed the time from gilteritinib initiation to either transplantation or death, considering these as first events and treating them as competing risks.</p>
<p>Secondary end points included response to gilteritinib assessed as the proportion of patients who achieved CR, CR with incomplete hematologic recovery (CRi), partial response (PR), or no response (NR) according to the 2022 European LeukemiaNet (ELN) recommendations.<a href="#cncr70055-bib-0018" class="usa-link" aria-describedby="cncr70055-bib-0018">
<sup>18</sup>
</a>
</p>
<p>Time‐to‐response was defined as the interval from gilteritinib initiation to the achievement of CR, CRh, or CRi. In responders, the duration of response was defined as the time from the achievement of CR or CRi to the loss of response (relapse or toxicity, considering transplant as a competing risk). For the SCT‐eligible group, we also analyzed posttransplant survival, defined as the time from allogeneic SCT to death from any cause.</p></section><section id="cncr70055-sec-0070"><h4 class="pmc_sec_title">Statistical methods</h4>
<p>The distribution of continuous variables was described by median, first and third quartiles, minimum, and maximum; categorical variables were reported as absolute and relative frequencies.</p>
<p>The overall survival was analyzed using the Kaplan–Meier estimator. The curves were estimated on the overall sample and within each group (post‐SCT, SCT‐eligible, and SCT‐not‐eligible). Comparison of survival curves were performed using the log‐rank test and were made by <em>FLT3</em> mutation already present at diagnosis versus not present, presence versus absence of other mutations (<em>NPM1</em>, <em>IDH1‐2</em>, <em>DNMT3A</em>, and <em>TP53</em>), gilteritinib initiation after a single line of chemotherapy versus multiple lines of chemotherapy, and previous tyrosine kinase inhibitor (TKI) treatment versus no treatment.</p>
<p>Posttransplant survival was also estimated using the Kaplan–Meier estimator on patients who received SCT.</p>
<p>Only for the SCT‐eligible group, the crude cumulative incidences of death as first event or transplant (competing risks) were analyzed using the Aalen–Johansen estimator. To analyze the duration of response, a competing risk analysis was performed also on patients who reached CR or complete remission with partial hematologic recovery considering (progression)/relapse/toxicity and transplant as competing events.</p></section></section></section><section id="cncr70055-sec-0080"><h2 class="pmc_sec_title">RESULTS</h2>
<p>A total of 205 patients were enrolled in the EAP of gilteritinib and included in this analysis.</p>
<section id="cncr70055-sec-0090"><h3 class="pmc_sec_title">Previous treatments</h3>
<p>Of the 205 patients included in the study, 163 (79.5%) received intensive chemotherapy as induction before initiating gilteritinib. The remaining 42 patients (20.5%) were initially treated with less‐intensive chemotherapy; among these, 35 were deemed ineligible for allo‐SCT.</p>
<p>Within the cohort of 163 patients treated with intensive induction, 39 relapsed after allo‐SCT, whereas the remaining 124 were transplant‐eligible patients who either relapsed following intensive chemotherapy (<em>n</em> = 82) or were primary refractory to it (<em>n</em> = 42).</p>
<p>Among these 124 transplant‐eligible patients, 99 (79.8%) had received standard “7 + 3” induction chemotherapy, with midostaurin administered in 64.5% (<em>n</em> = 80) of cases. The remaining 25 patients (20.2%) were treated with alternative induction regimens, including FLAI (fludarabine, cytarabine, and idarubicin), ICE (idarubicin, cytarabine, and etoposide), or liposomal daunorubicin–cytarabine (CPX‐351).</p>
<p>Patients classified as primary refractory subsequently received second‐line intensive chemotherapy, most commonly FLAG‐Ida (fludarabine, cytarabine, and idarubicin) or MEC (mitoxantrone, etoposide, and cytarabine). Additional salvage treatments included venetoclax combined with a hypomethylating agent (azacitidine or decitabine).</p>
<p>Among the 39 patients who relapsed after allo‐SCT, 30 had received the standard “7 + 3” induction chemotherapy combined with midostaurin. Overall, of the 163 patients treated with intensive regimens, 110 (67.5%) had prior exposure to a TKI before starting gilteritinib, whereas 53 (32.5%) had not.</p></section><section id="cncr70055-sec-0100"><h3 class="pmc_sec_title">Indication for receiving gilteritinib</h3>
<p>A total of 148 patients (72.2%) received gilteritinib at the time of relapse, whereas 57 patients (27.8%) were treated for primary refractory disease. Based on relapse after allo‐SCT or transplant eligibility, patients were categorized into three groups.</p>
<p>The posttransplant relapse group included 46 patients who received gilteritinib following relapse after transplantation.</p>
<p>The non–transplant‐eligible group included 35 patients, with a median age of 75 years, who received less‐intensive chemotherapy and were deemed ineligible for HSCT. Before gilteritinib initiation, 17 patients had been treated with azacitidine and venetoclax (median 3 cycles; range, 2–11), 11 with decitabine alone (median 7 cycles; range, 1–28), and seven with azacitidine alone (median 10 cycles; range, 2–16). Among the 17 patients treated with azacitidine and venetoclax (VEN‐AZA), 14 of 17 (82%) were classified as ELN 2017 adverse risk, and 12 of 17 (70.5%) presented with hyperleukocytosis at the time of gilteritinib initiation and received hidroxyurea for citoreduction. Based on their response to prior therapy, 15 patients were categorized as having primary refractory disease, and 20 patients were categorized as having relapsed disease.</p>
<p>Gilteritinib was administered as monotherapy until disease progression or the development of unacceptable toxicity. Notably, one patient in this cohort—initially considered ineligible for transplant—ultimately proceeded to transplantation.</p>
<p>The transplant‐eligible group comprised 124 patients, including 82 with relapsed disease and 42 with primary refractory disease, who received gilteritinib as a bridging therapy before transplantation.</p>
<p>Among those with primary refractory disease, 32 were refractory to a single course of intensive chemotherapy, whereas 10 were refractory to two or more courses.</p>
<p>The median age at diagnosis was 60 years and differed significantly among the three subgroups, as determined by the Kruskal–Wallis test (<em>p</em> value &lt;.01). Patients in the transplant‐not‐eligible group were the oldest, with a median age of 75 years. Table <a href="#cncr70055-tbl-0001" class="usa-link">1</a>.</p>
<section class="tw xbox font-sm" id="cncr70055-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Patient demographics and clinical characteristics.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Overall</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Relapsed posttransplant</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Transplant ineligible</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Transplant eligible</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total population</td>
<td align="left" valign="top" rowspan="1" colspan="1">205</td>
<td align="left" valign="top" rowspan="1" colspan="1">46</td>
<td align="left" valign="top" rowspan="1" colspan="1">35</td>
<td align="left" valign="top" rowspan="1" colspan="1">124</td>
</tr>
<tr><td colspan="5" align="left" valign="top" rowspan="1">Age (years) at diagnosis</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median</td>
<td align="left" valign="top" rowspan="1" colspan="1">60</td>
<td align="left" valign="top" rowspan="1" colspan="1">55</td>
<td align="left" valign="top" rowspan="1" colspan="1">75</td>
<td align="left" valign="top" rowspan="1" colspan="1">57</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Range</td>
<td align="left" valign="top" rowspan="1" colspan="1">(18–87)</td>
<td align="left" valign="top" rowspan="1" colspan="1">(18–72)</td>
<td align="left" valign="top" rowspan="1" colspan="1">(53–87)</td>
<td align="left" valign="top" rowspan="1" colspan="1">(22–82)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IQR range</td>
<td align="left" valign="top" rowspan="1" colspan="1">(49–70)</td>
<td align="left" valign="top" rowspan="1" colspan="1">(47.25–62)</td>
<td align="left" valign="top" rowspan="1" colspan="1">(73–79)</td>
<td align="left" valign="top" rowspan="1" colspan="1">(48–66)</td>
</tr>
<tr><td colspan="5" align="left" valign="top" rowspan="1">Gender, No. (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female</td>
<td align="left" valign="top" rowspan="1" colspan="1">111 (54.1)</td>
<td align="left" valign="top" rowspan="1" colspan="1">28 (60.9)</td>
<td align="left" valign="top" rowspan="1" colspan="1">15 (42.9)</td>
<td align="left" valign="top" rowspan="1" colspan="1">68 (54.8)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male</td>
<td align="left" valign="top" rowspan="1" colspan="1">94 (45.9)</td>
<td align="left" valign="top" rowspan="1" colspan="1">18 (39.1)</td>
<td align="left" valign="top" rowspan="1" colspan="1">20 (57.1)</td>
<td align="left" valign="top" rowspan="1" colspan="1">56 (45.2)</td>
</tr>
<tr><td colspan="5" align="left" valign="top" rowspan="1">WBC at diagnosis (×10<sup>9</sup>/L)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IQR range</td>
<td align="left" valign="top" rowspan="1" colspan="1">37</td>
<td align="left" valign="top" rowspan="1" colspan="1">25</td>
<td align="left" valign="top" rowspan="1" colspan="1">13.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">60</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median</td>
<td align="left" valign="top" rowspan="1" colspan="1">1–398</td>
<td align="left" valign="top" rowspan="1" colspan="1">2.45–327</td>
<td align="left" valign="top" rowspan="1" colspan="1">1–263</td>
<td align="left" valign="top" rowspan="1" colspan="1">1.59–398</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Range</td>
<td align="left" valign="top" rowspan="1" colspan="1">11–97.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">9–65</td>
<td align="left" valign="top" rowspan="1" colspan="1">3.6–32.1</td>
<td align="left" valign="top" rowspan="1" colspan="1">18–121</td>
</tr>
<tr><td colspan="5" align="left" valign="top" rowspan="1">AML status: No. (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">De novo AML</td>
<td align="left" valign="top" rowspan="1" colspan="1">150 (73.2)</td>
<td align="left" valign="top" rowspan="1" colspan="1">30 (65.2)</td>
<td align="left" valign="top" rowspan="1" colspan="1">17 (48.6)</td>
<td align="left" valign="top" rowspan="1" colspan="1">103 (83.1)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Secondary AML</td>
<td align="left" valign="top" rowspan="1" colspan="1">55 (26.8)</td>
<td align="left" valign="top" rowspan="1" colspan="1">16 (34.8)</td>
<td align="left" valign="top" rowspan="1" colspan="1">18 (51.4)</td>
<td align="left" valign="top" rowspan="1" colspan="1">21 (16.9)</td>
</tr>
<tr><td colspan="5" align="left" valign="top" rowspan="1">ELN 2017, No. (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Favorable</td>
<td align="left" valign="top" rowspan="1" colspan="1">42 (20.5)</td>
<td align="left" valign="top" rowspan="1" colspan="1">8 (17.4)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (11.4)</td>
<td align="left" valign="top" rowspan="1" colspan="1">30 (24.2)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Intermediate</td>
<td align="left" valign="top" rowspan="1" colspan="1">79 (38.5)</td>
<td align="left" valign="top" rowspan="1" colspan="1">18 (39.1)</td>
<td align="left" valign="top" rowspan="1" colspan="1">12 (34.3)</td>
<td align="left" valign="top" rowspan="1" colspan="1">49 (39.5)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adverse</td>
<td align="left" valign="top" rowspan="1" colspan="1">82 (40.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">20 (43.5)</td>
<td align="left" valign="top" rowspan="1" colspan="1">19 (54.3)</td>
<td align="left" valign="top" rowspan="1" colspan="1">43 (34.7)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown</td>
<td align="left" valign="top" rowspan="1" colspan="1">2 (1.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">2 (1.6)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Extramedullary disease, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">14 (6.8)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3 (6.5)</td>
<td align="left" valign="top" rowspan="1" colspan="1">2 (5.7)</td>
<td align="left" valign="top" rowspan="1" colspan="1">9 (7.3)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<em>FLT3</em> mutation at diagnosis, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">175/205 (85.4)</td>
<td align="left" valign="top" rowspan="1" colspan="1">42/46 (91.3)</td>
<td align="left" valign="top" rowspan="1" colspan="1">25/35 (71.4)</td>
<td align="left" valign="top" rowspan="1" colspan="1">108/124 (87.1)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>FLT3</em>‐ITD</td>
<td align="left" valign="top" rowspan="1" colspan="1">147/175 (84.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">34/42 (81.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">19/25 (76.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">94/108 (87.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<em>FLT3‐</em>TKD</td>
<td align="left" valign="top" rowspan="1" colspan="1">23/175 (13.1)</td>
<td align="left" valign="top" rowspan="1" colspan="1">7/42 (16.7)</td>
<td align="left" valign="top" rowspan="1" colspan="1">6/25 (24.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">10/108 (9.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Both</td>
<td align="left" valign="top" rowspan="1" colspan="1">5/175 (2.9)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1/42 (2.4)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4/108 (3.7)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<em>FLT3</em> mutation at relapse, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">27/205 (13.2)</td>
<td align="left" valign="top" rowspan="1" colspan="1">4/42 (8.7)</td>
<td align="left" valign="top" rowspan="1" colspan="1">10/35 (28.6)</td>
<td align="left" valign="top" rowspan="1" colspan="1">16/124 (12.9)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">NA, No. (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">3/205 (1.4)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">2 (5.7)</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (0.8)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/cncr70055-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="cncr70055-note-0001"><p>Abbreviations: AML, acute myeloid leukemia; ELN, European LeukemiaNet; ITD, internal tandem duplications; IQR, interquartile range; NA, not available; TKD, tyrosine kinase domain; WBC, white blood cell.</p></div></div></section><p>A detailed breakdown of treatment regimens for each group is provided in Table <a href="#cncr70055-tbl-0002" class="usa-link">2</a>.</p>
<section class="tw xbox font-sm" id="cncr70055-tbl-0002"><h4 class="obj_head">TABLE 2.</h4>
<div class="caption p"><p>Clinical and treatment features of FLT3‐positive R/R AML patients by transplant status.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Overall (<em>n</em> = 205)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Relapsed posttransplant (<em>n</em> = 46)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Transplant ineligible (<em>n</em> = 35)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Transplant eligible (<em>n</em> = 124)</th>
</tr></thead>
<tbody valign="top">
<tr><td colspan="5" align="left" valign="top" rowspan="1">Disease status, No. (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Relapsed</td>
<td align="center" valign="top" rowspan="1" colspan="1">148 (72.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">46 (100.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">20 (57.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">82 (66.1)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Primary refractory</td>
<td align="center" valign="top" rowspan="1" colspan="1">57 (27.8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 (42.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">42 (33.3)</td>
</tr>
<tr><td colspan="5" align="left" valign="top" rowspan="1">Allogeneic transplant status, No. (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Did not receive transplant</td>
<td align="center" valign="top" rowspan="1" colspan="1">99 (48.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">34 (97.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">65 (52.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Patients receiving gilteritinib posttransplant</td>
<td align="center" valign="top" rowspan="1" colspan="1">46 (22.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">46 (100.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Patients receiving gilteritinib as bridge to transplant</td>
<td align="center" valign="top" rowspan="1" colspan="1">60 (29.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (2.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">59 (47.6)</td>
</tr>
<tr><td colspan="5" align="left" valign="top" rowspan="1">Prior chemotherapy, No. (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Intensive chemotherapy</td>
<td align="center" valign="top" rowspan="1" colspan="1">163 (79.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">39 (84.8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">124 (100.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">TKI</td>
<td align="center" valign="top" rowspan="1" colspan="1">113 (55.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">32 (69.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (2.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">80 (64.5)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Less‐Intensive chemotherapy</td>
<td align="center" valign="top" rowspan="1" colspan="1">42 (20.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">7 (15.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">35 (100.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/cncr70055-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="cncr70055-note-0002"><p>Abbreviations: AML, acute myeloid leukemia; TKI, tyrosine kinase inhibitor; R/R, relapsed or refractory.</p></div></div></section></section><section id="cncr70055-sec-0110"><h3 class="pmc_sec_title">Genetic landscape at diagnosis and at relapse</h3>
<p>Most patients had de novo AML (73%), with an intermediate (38%) or adverse (40%) risk profile according to the ELN 2017 classification.<a href="#cncr70055-bib-0019" class="usa-link" aria-describedby="cncr70055-bib-0019">
<sup>19</sup>
</a>
</p>
<p>
<em>FLT3</em> mutations were present in 175 of 205 patients (85.4%) at diagnosis, whereas 30 patients (14.6%) acquired the mutation at relapse.</p>
<p>At diagnosis, <em>FLT3</em>‐ITD was identified in 147 of 175 patients (84.0%), whereas 23 of 175 patients (13.1%) exhibited the <em>FLT3</em>‐TKD mutation; five patients (2.9%) had both FLT3‐ITD and FLT3‐TKD mutations.</p>
<p>Among the 175 patients who presented with an <em>FLT3</em>‐ITD/TKD mutation, 116 (66.3%) had co‐occurring mutations, either alone or in combination, including <em>NPM1</em> (83 of 175 = 47.4%), <em>DNMT3A</em> (17 of 175 = 9.7%), <em>IDH1/IDH2</em> (12 of 175 = 6.9%), and <em>TP53</em> (four of 175 = 2.3%).</p>
<p>Among the 30 patients who acquired <em>FLT3</em> mutations at relapse, <em>NPM1</em> was the most frequently co‐mutated gene, occurring either alone or in combination with other mutations in 12 of 30 patients (40.0%). Other co‐mutations included <em>IDH1/IDH2</em> in five of 30 (16.7%) and <em>TP53</em> in two of 30 (6.7%) patients.</p>
<p>The most prevalent co‐mutations at diagnosis and relapse are summarized in Figure <a href="#cncr70055-fig-0001" class="usa-link">1</a>, with a detailed overview of the genomic landscape at both time points available in Table <a href="#cncr70055-sup-0001" class="usa-link">S1</a>.</p>
<figure class="fig xbox font-sm" id="cncr70055-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc23/12369923/5bd2ca1846e8/CNCR-131-e70055-g001.jpg" loading="lazy" id="jats-graphic-1" height="251" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70055-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Bar charts depicting the most frequent co‐mutated genes among patients who had <em>FLT3</em> mutations at diagnosis (A) and those who acquired <em>FLT3</em> mutations after diagnosis (B). FLT3‐ITD/TKD: Internal tandem duplication or tyrosine kinase domain mutations in the <em>FLT3</em> gene. <em>DNMT3A</em> indicates DNA methyltransferase 3 α gene mutation; <em>IDH1/2</em>, isocitrate dehydrogenase 1 or 2 gene mutations; <em>NPM1</em>, nucleophosmin 1 gene mutation; <em>TP53</em>, tumor protein p53 gene mutation.</p></figcaption></figure></section><section id="cncr70055-sec-0120"><h3 class="pmc_sec_title">Treatment outcome and prognostic factors</h3>
<p>Among the total cohort of 205 patients who received gilteritinib, a CR rate of 43.4% (89/205) was observed, whereas the CR with CRi rate was 8.8% (18 of 205). Overall, 52.2% (107 of 205) of patients achieved a substantial response (CR or CRi). The median OS was 10.3 months, with a 1‐year OS probability of 44.4% (95% confidence interval [CI], 37.8–52.2) and a 3‐year OS probability of 21.3% (95% CI, 15.8–28.7) (Figure <a href="#cncr70055-fig-0002" class="usa-link">2A</a>; Table <a href="#cncr70055-tbl-0003" class="usa-link">3</a>)</p>
<figure class="fig xbox font-sm" id="cncr70055-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc23/12369923/a7457a0f9f7f/CNCR-131-e70055-g002.jpg" loading="lazy" id="jats-graphic-3" height="986" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70055-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>OS based on transplant eligibility and refractoriness to intensive chemotherapy. Kaplan–Meier curves showing OS in the full patient cohort (A) and stratified by transplant status: relapse posttransplant (B), transplant‐ineligible (C), and transplant‐eligible (D). (E and F) OS in patients refractory to intensive chemotherapy, with (F) further stratifying by number of prior chemotherapy lines (one line vs. two or more lines). OS indicates overall survival.</p></figcaption></figure><section class="tw xbox font-sm" id="cncr70055-tbl-0003"><h4 class="obj_head">TABLE 3.</h4>
<div class="caption p"><p>Treatment responses in R/R patients post‐intensive chemotherapy: Outcomes by transplant eligibility and prior treatment.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th colspan="4" align="left" valign="bottom" rowspan="1">All patients (R/R)</th>
<th colspan="3" align="left" valign="bottom" rowspan="1">Refractory to intensive chemotherapy</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Response</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Overall</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Relapsed posttransplant</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Transplant ineligible<a href="#cncr70055-note-0005" class="usa-link">
<sup>b</sup>
</a>
</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Transplant elegible<a href="#cncr70055-note-0006" class="usa-link">
<sup>c</sup>
</a>
</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Overall</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Refractory to one line<a href="#cncr70055-note-0004" class="usa-link">
<sup>a</sup>
</a>
</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Refractory to two or more lines<a href="#cncr70055-note-0004" class="usa-link">
<sup>a</sup>
</a>
<sup>,</sup>
<a href="#cncr70055-note-0007" class="usa-link">
<sup>d</sup>
</a>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">CR, No. (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">89 (43.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">21 (45.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (8.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">65 (52.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">22 (52.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">19 (59.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (30.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">CRi, No. (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">18 (8.8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (8.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (2.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">13 (10.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (9.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (9.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (10.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">PR, No. (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">25 (12.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (4.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 (22.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 (12.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (9.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (6.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (20.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">NR, No. (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">72 (35.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">19 (41.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">23 (65.8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">30 (24.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">12 (28.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 (25.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (40.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">NA, No. (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (0.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (0.8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Patient, No. (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">205 (100.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">46 (100.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">35 (100.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">124 (100.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">42 (100.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">32 (100.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (100.0)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/cncr70055-tbl-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="cncr70055-note-0003"><p>Abbreviations: CR, complete remission; CRi, CR with incomplete hematologic recovery; NA, not available—data not available or missing; NR, no response—failure to meet criteria for CR, CRi, or PR; PR, partial response; R/R, relapsed or refractory.</p></div>
<div class="fn" id="cncr70055-note-0004">
<sup>
<sup>a</sup>
</sup><p class="display-inline">No significant differences were found between patients refractory to one line and to two or more lines of intensive chemotherapy in terms of response (Fisher test, <em>p</em> value = .142).</p>
</div>
<div class="fn" id="cncr70055-note-0005">
<sup>
<sup>b</sup>
</sup><p class="display-inline">Patients not considered candidates for transplant due to age, comorbidities, or other factors.</p>
</div>
<div class="fn" id="cncr70055-note-0006">
<sup>
<sup>c</sup>
</sup><p class="display-inline">Patients who were deemed fit for potential stem cell transplantation.</p>
</div>
<div class="fn" id="cncr70055-note-0007">
<sup>
<sup>d</sup>
</sup><p class="display-inline">Patients who failed at least two prior lines of intensive chemotherapy.</p>
</div>
</div></section><section id="cncr70055-sec-0130"><h4 class="pmc_sec_title">Outcomes of gilteritinib treatment after allo‐SCT</h4>
<p>Among the 46 patients who experienced relapse following allogeneic transplantation, treatment with gilteritinib resulted in an overall response rate (ORR) of 54.3% (25 of 46). A total of 45.7% (21 of 46) of patients achieved CR, whereas an additional 8.7% (four of 46) attained CR with CRi. The median time to response was 66 days (Table <a href="#cncr70055-tbl-0004" class="usa-link">4</a>). The median OS was 11.1 months, with an OS probability of 49.5% (95% CI, 36.6–67.0) at 1 year and 15.5% (95% CI, 7.15–33.6) at 3 years. The Kaplan–Meier survival curve in patients who received gilteritinib as salvage therapy following allogeneic stem cell transplantation (post‐SCT group) is presented in Figure <a href="#cncr70055-fig-0002" class="usa-link">2B</a>.</p>
<section class="tw xbox font-sm" id="cncr70055-tbl-0004"><h5 class="obj_head">TABLE 4.</h5>
<div class="caption p"><p>Clinical outcomes with gilteritinib: Insights from Admiral trial and real‐world evidence by country.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Study</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Patients (<em>n</em>)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Median OS (months)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">CR (%)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">CRi (%)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">CRp</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">PR (%)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">NR (%)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">NA (%)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Ref.</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Italy</td>
<td align="center" valign="top" rowspan="1" colspan="1">205</td>
<td align="center" valign="top" rowspan="1" colspan="1">10.3</td>
<td align="center" valign="top" rowspan="1" colspan="1">43.4</td>
<td align="center" valign="top" rowspan="1" colspan="1">8.8</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">12.2</td>
<td align="center" valign="top" rowspan="1" colspan="1">35.1</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Admiral</td>
<td align="center" valign="top" rowspan="1" colspan="1">247</td>
<td align="center" valign="top" rowspan="1" colspan="1">9.3</td>
<td align="center" valign="top" rowspan="1" colspan="1">21.1</td>
<td align="center" valign="top" rowspan="1" colspan="1">25.5</td>
<td align="center" valign="top" rowspan="1" colspan="1">13.4</td>
<td align="center" valign="top" rowspan="1" colspan="1">13.4</td>
<td align="center" valign="top" rowspan="1" colspan="1">26.6</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">France</td>
<td align="center" valign="top" rowspan="1" colspan="1">140</td>
<td align="center" valign="top" rowspan="1" colspan="1">6.4</td>
<td align="center" valign="top" rowspan="1" colspan="1">25.4<a href="#cncr70055-note-0009" class="usa-link">
<sup>a</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">5.2</td>
<td align="center" valign="top" rowspan="1" colspan="1">52.4</td>
<td align="center" valign="top" rowspan="1" colspan="1">10</td>
<td align="center" valign="top" rowspan="1" colspan="1">12</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Germany</td>
<td align="center" valign="top" rowspan="1" colspan="1">156</td>
<td align="center" valign="top" rowspan="1" colspan="1">6.2</td>
<td align="center" valign="top" rowspan="1" colspan="1">43.6<a href="#cncr70055-note-0009" class="usa-link">
<sup>a</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">23.7</td>
<td align="center" valign="top" rowspan="1" colspan="1">25</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">19</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Japan</td>
<td align="center" valign="top" rowspan="1" colspan="1">67</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">34.3</td>
<td align="center" valign="top" rowspan="1" colspan="1">23.9</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.5</td>
<td align="center" valign="top" rowspan="1" colspan="1">20.9</td>
<td align="center" valign="top" rowspan="1" colspan="1">11.9</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.5</td>
<td align="center" valign="top" rowspan="1" colspan="1">9</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">United Kingdom</td>
<td align="center" valign="top" rowspan="1" colspan="1">152</td>
<td align="center" valign="top" rowspan="1" colspan="1">9.5</td>
<td align="center" valign="top" rowspan="1" colspan="1">20.5</td>
<td align="center" valign="top" rowspan="1" colspan="1">8.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">27.6</td>
<td align="center" valign="top" rowspan="1" colspan="1">31.5</td>
<td align="center" valign="top" rowspan="1" colspan="1">4</td>
<td align="center" valign="top" rowspan="1" colspan="1">14</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Israel</td>
<td align="center" valign="top" rowspan="1" colspan="1">25</td>
<td align="center" valign="top" rowspan="1" colspan="1">8</td>
<td align="center" valign="top" rowspan="1" colspan="1">48</td>
<td align="center" valign="top" rowspan="1" colspan="1">12</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">40</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">15</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Turkey</td>
<td align="center" valign="top" rowspan="1" colspan="1">17</td>
<td align="center" valign="top" rowspan="1" colspan="1">11.8</td>
<td align="center" valign="top" rowspan="1" colspan="1">64.7</td>
<td align="center" valign="top" rowspan="1" colspan="1">5.9</td>
<td align="center" valign="top" rowspan="1" colspan="1">17.6</td>
<td align="center" valign="top" rowspan="1" colspan="1">11.8</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">20</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">United States</td>
<td align="center" valign="top" rowspan="1" colspan="1">113</td>
<td align="center" valign="top" rowspan="1" colspan="1">7</td>
<td align="center" valign="top" rowspan="1" colspan="1">22.1</td>
<td align="center" valign="top" rowspan="1" colspan="1">26.5<a href="#cncr70055-note-0010" class="usa-link">
<sup>b</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="left" valign="top" rowspan="1" colspan="1">—</td>
<td align="center" valign="top" rowspan="1" colspan="1">13</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/cncr70055-tbl-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="cncr70055-note-0008"><p>Abbreviations: CR, complete remission; CRi, complete remission with incomplete hematologic recovery; CRp, complete remission with incomplete platelet recovery; PR, partial response; NR, no response; NA, not available; OS, overall survival.</p></div>
<div class="fn" id="cncr70055-note-0009">
<sup>
<sup>a</sup>
</sup><p class="display-inline">CR and CRi reported as combined rate.</p>
</div>
<div class="fn" id="cncr70055-note-0010">
<sup>
<sup>b</sup>
</sup><p class="display-inline">CRi includes CRp where applicable.</p>
</div>
</div></section></section><section id="cncr70055-sec-0140"><h4 class="pmc_sec_title">Outcome in patients initially treated with less‐intensive chemotherapy and not eligible for allo‐SCT</h4>
<p>This cohort included 35 patients. Among them, 8.6% (three of 35) achieved CR, and an additional 2.9% (one of 35) attained CR with CRi, resulting in an ORR of 11.4% (4/35). The median OS was 5.9 months, with a 1‐year OS probability of 29.0% (95% CI, 16.6–50.8). The Kaplan–Meier survival curve for OS in the SCT‐not‐eligible group is shown in Figure <a href="#cncr70055-fig-0002" class="usa-link">2C</a>.</p>
<p>Furthermore, we observed a median survival of 7.5 months in the 17 patients who relapsed after or were refractory to venetoclax and azacitidine, compared with 5.3 months in the remaining 18 patients treated with other low‐intensity chemotherapy (<em>p</em> = .042) (Figure <a href="#cncr70055-sup-0001" class="usa-link">S1</a>).</p></section><section id="cncr70055-sec-0150"><h4 class="pmc_sec_title">Outcome in patients eligible for allo‐SCT</h4>
<p>A total of 124 patients, deemed eligible for intensive treatment according to the GITMO (Gruppo Italiano Trapianto Midollo Osseo) criteria,<a href="#cncr70055-bib-0020" class="usa-link" aria-describedby="cncr70055-bib-0020">
<sup>20</sup>
</a> received gilteritinib as a bridge to allogeneic transplantation. The ORR in this cohort was 78 of 124 (62.9%), with a median time to response of 63 days (Table <a href="#cncr70055-tbl-0003" class="usa-link">3</a>). CR was achieved in 65 of 124 patients (52.4%), whereas an additional 13 patients attained CR with CRi (10.5%).</p>
<p>The Kaplan–Meier survival curve for OS in this cohort is depicted in Figure <a href="#cncr70055-fig-0002" class="usa-link">2D</a>. The median OS was 11.0 months, with an estimated OS probability of 46.8% (95% CI, 38.4–57.0) at 1 year and 28.5% (95% CI, 21.0–38.7) at 3 years.</p>
<p>Sixty patients (48%) proceeded to transplantation after a median of 112 days (3.7 months), with a crude incidence of transplantation at 1 year of 47.1% (95% CI, 38.2–56.0) (Figure <a href="#cncr70055-sup-0001" class="usa-link">S2</a>). Posttransplant survival was 65.2% (95% CI, 53.0–80.3) at 1 year and 56.1% (95% CI, 43.5–72.4) at 3 years (Figure <a href="#cncr70055-sup-0001" class="usa-link">S3</a>).</p></section><section id="cncr70055-sec-0160"><h4 class="pmc_sec_title">Outcomes in patients refractory to single versus multiple lines of intensive chemotherapy</h4>
<p>The median OS for the 42 patients refractory to intensive chemotherapy was 11.0 months. The OS probability was 44.2% (95% CI, 31.1–63.0) at 1 year and 27.9% (95% CI, 16.7–46.6) at 3 years (Figure <a href="#cncr70055-fig-0002" class="usa-link">2E</a>). The overall response rate was 61.9% (Table <a href="#cncr70055-tbl-0003" class="usa-link">3</a>). No significant difference was observed between the 10 single‐refractory patients and the 32 multi‐refractory patients (two or more lines of chemotherapy) in terms of either survival (<em>p</em> = .32) or response (<em>p</em> = .142) to gilteritinib (Figure <a href="#cncr70055-fig-0002" class="usa-link">2F</a>).</p></section><section id="cncr70055-sec-0170"><h4 class="pmc_sec_title">Outcome of patients achieving CR or CRi</h4>
<p>Among the subgroup of 107 patients who achieved CR or CR with CRi, the probabilities of undergoing a transplant from the time of response were 46.1% (95% CI, 36.5–55.6) at 1 year and 47.1% (95% CI, 37.5–56.7) at 3 years. In contrast, the probability of relapse or death within 1 year was 29.8% (95% CI, 21.0–38.6), increasing to 40.7% (95% CI, 30.7–50.6) at 3 years following the achievement of response (Figure <a href="#cncr70055-fig-0003" class="usa-link">3</a>).</p>
<figure class="fig xbox font-sm" id="cncr70055-fig-0003"><h5 class="obj_head">FIGURE 3.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc23/12369923/160419cadd5c/CNCR-131-e70055-g003.jpg" loading="lazy" id="jats-graphic-5" height="546" width="709" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70055-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Outcomes following CR or CR with CRi. Crude cumulative incidences of hematopoietic stem cell transplant (blue line) and relapse or toxicity (orange line) in patients who achieved CR or CR with CRi. Events were analyzed using a competing risks framework from the time of best response. Shaded areas represent 95% CIs. Number at risk: patients remaining in follow‐up without either event at each time point. CI indicates confidence interval; CR, complete remission; CRi, incomplete hematologic recovery.</p></figcaption></figure><p>Notably, patients with CR experienced a significantly better OS compared to those who achieved CR with CRi (Figure <a href="#cncr70055-sup-0001" class="usa-link">S4</a>). The 1‐ and 3‐year survival probabilities in the CR group were 65.3% (95% CI, 55.6–76.6) and 39.6% (95% CI, 29.6–53.0), respectively, compared to 36.1% (95% CI, 19.2–68.1) and 12.0% (95% CI, 3.3–44.0) in the CRi group.</p></section><section id="cncr70055-sec-0180"><h4 class="pmc_sec_title">Prognostic impact of genetic features on survival in patients receiving gilteritinib</h4>
<p>In the cohort of patients who received gilteritinib as a bridge to transplantation, the acquisition of a <em>FLT3</em> mutation or the presence of a <em>TP53</em> co‐mutation was associated with significantly reduced survival probability (<em>p</em> = .0066 and <em>p</em> = .022, respectively), as well as a poorer response rate. In contrast, co‐mutations in <em>NPM1</em>, <em>IDH1/2</em>, or <em>DNMT3A</em> did not significantly affect survival outcomes (Figure <a href="#cncr70055-sup-0001" class="usa-link">S5</a>; Table <a href="#cncr70055-sup-0001" class="usa-link">S2</a>).</p>
<p>In the cohort of 46 patients who received gilteritinib for relapse after transplantation, those who acquired the FLT3 mutation had a trend toward worse prognosis, although this did not reach statistical significance (<em>p</em> = .064). The presence of co‐mutations in <em>TP53</em>, <em>NPM1</em>, <em>IDH1/2</em>, or <em>DNMT3A</em> did not significantly impact survival probability (Figure <a href="#cncr70055-sup-0001" class="usa-link">S6</a>).</p>
<p>In the group of patients not eligible to transplantation, no significant differences were found based on the presence or absence of the different co‐mutations in terms of overall survival (Figure <a href="#cncr70055-sup-0001" class="usa-link">S7</a>).</p></section><section id="cncr70055-sec-0190"><h4 class="pmc_sec_title">Impact of previous treatment with <em>FLT3</em> inhibitors</h4>
<p>A total of 113 patients had prior exposure to <em>FLT3</em> inhibitors before initiating gilteritinib. Of these, 110 patients received midostaurin during “3 + 7” induction (including two who also received posttransplant sorafenib), and three patients received sorafenib posttransplant only. Among the 163 patients who underwent intensive chemotherapy, those with prior <em>FLT3</em> inhibitor exposure (110 patients) demonstrated significantly improved OS compared to those without such exposure (53 patients) (log‐rank test, <em>p</em> = .0025). The Kaplan–Meier survival curves for the two groups are presented in Figure <a href="#cncr70055-sup-0001" class="usa-link">S8</a>. In the TKI‐exposed group, the median OS was 13.2 months, with 1‐year and 3‐year survival rates of 51.3% (95% CI, 42.4–62.2) and 33.9% (95% CI, 25.4–45.1), respectively. In contrast, patients without prior TKI exposure had a median OS of 8.0 months, with 1‐year and 3‐year survival rates of 38.4% (95% CI, 26.9–54.9) and 11.1% (95% CI, 4.6–27.8), respectively. The two subgroups differed in baseline characteristics, including age distribution, ELN risk classification, and AML type (secondary vs. de novo). Patients with prior TKI exposure were younger, with a median age of 55 years compared to 58 years in the No‐TKI group. Additionally, the TKI group had a lower proportion of patients with adverse ELN risk (32.7% vs. 45.3%) and secondary AML (13.6% vs. 47.2%).</p></section></section></section><section id="cncr70055-sec-0200"><h2 class="pmc_sec_title">DISCUSSION</h2>
<p>The analysis of clinical data from patients enrolled in the gilteritinib EAP across Italian hospitals confirms the treatment’s efficacy in improving overall survival and response rates. To the best of our knowledge, this represents the largest cohort of R/R AML patients treated with gilteritinib outside the setting of a clinical trial to date.</p>
<p>At diagnosis (175), <em>FLT3</em> mutation was present in 175 patients (85.4% of the total). Among these, the majority harbored the <em>FLT3</em>‐ITD mutation (84%), whereas 13.1% exhibited <em>FLT3</em>‐TKD and 2.9% had both ITD and TKD mutations. The most frequently observed co‐mutations were <em>NPM1</em> (47.4%) and <em>DNMT3A</em> (40%), consistent with previous reports.<a href="#cncr70055-bib-0008" class="usa-link" aria-describedby="cncr70055-bib-0008">
<sup>8</sup>
</a> Notably, 14.6% of patients (30 patients) acquired an <em>FLT3</em> mutation at relapse, underscoring the importance of <em>FLT3</em> retesting in this setting. At relapse, <em>NPM1</em> remained the most commonly mutated gene (40%), whereas <em>DNMT3A</em> mutations were not detected. Considering the entire cohort of 205 patients who received gilteritinib, we observed an ORR of 52.2%, with a CR rate of 43.4% and a CR with CRi rate of 8.8%.</p>
<p>To better understand the therapeutic potency of gilteritinib in different clinical contexts, we analyzed outcomes in three distinct groups: 1) patients fit for intensive chemotherapy and candidates for allogeneic transplantation; 2) patients who relapsed after an allogeneic transplant; and 3) patients who experienced relapse or progression after less‐intensive chemotherapy and received gilteritinib until progression or unacceptable toxicity. As expected, the three groups were not matched for age and performance status, with a significantly older median age (75 years) among patients unfit for intensive chemotherapy. The best outcomes were observed in the 124 patients treated with gilteritinib as a bridge to transplantation. The ORR in this cohort was 62.9%, with a CR rate of 52.2%. Nearly half of the patients in this cohort (47.6%) successfully proceeded to transplantation after a median of 3.7 months. Posttransplant survival was 65.2% (95% CI, 53.0–80.3) at 1 year and 56.1% (95% CI, 43.5–72.4) at 3 years (Figure <a href="#cncr70055-sup-0001" class="usa-link">S3</a>). Among this group, patients who acquired the <em>FLT3</em> mutation at relapse and those with a <em>TP53</em> mutation had significantly worse outcomes, with higher mortality, a reduced response rate, and a lower number of patients proceeding to transplantation (Figure <a href="#cncr70055-sup-0001" class="usa-link">S5</a>). Additionally, we did not observe a statistically significant difference in response to gilteritinib between patients refractory to one course versus multiple courses of intensive chemotherapy.</p>
<p>Gilteritinib has also shown activity in patients who relapsed following allogeneic HSCT. In this subset, the ORR was 54%, with a CR rate of 45.7% and a median time to response of 66 days. Kaplan–Meier analysis revealed an OS probability of 49.5% at 1 year, which declined to 15.6% at 3 years. The presence of co‐mutations—including <em>NPM1</em>, <em>IDH1/2</em>, <em>TP53</em>, and <em>DNMT3A</em>—did not significantly impact survival outcomes. However, patients with <em>FLT3</em> mutations detected at diagnosis showed a trend toward inferior outcomes, although the difference was not statistically significant (<em>p</em> = .064). These findings underscore the need for additional strategies to sustain responses to gilteritinib in the posttransplant setting. One potential approach is prophylactic unmanipulated donor lymphocyte infusion as maintenance therapy, which has been recommended in recent expert guidelines.<a href="#cncr70055-bib-0021" class="usa-link" aria-describedby="cncr70055-bib-0021">
<sup>21</sup>
</a>
</p>
<p>An unexpected finding in our study was that prior treatment with an <em>FLT3</em> inhibitor was associated with significantly improved survival compared with patients without such exposure. However, this observation should be interpreted with caution, as the two subgroups differed substantially in baseline characteristics. Patients who had received a prior <em>FLT3</em> inhibitor were younger (median age, 55 vs. 58 years), had a lower proportion of adverse ELN risk classification (32.7% vs. 45.3%), and were less likely to have secondary AML (13.6% vs. 47.2%). These imbalances suggest that the observed survival advantage may, at least in part, reflect more favorable baseline prognostic factors rather than a direct effect of prior <em>FLT3</em> inhibitor therapy. Multivariate analyses adjusting for these potential confounders would be necessary to clarify the independent impact of prior <em>FLT3</em> inhibitor exposure; however, such analyses were not performed in the present study.</p>
<p>Notably, our findings are consistent with reports from the Spanish CETLAM and PETHEMA groups, which also demonstrated improved overall survival among patients previously treated with <em>FLT3</em> inhibitors compared with unexposed individuals.<a href="#cncr70055-bib-0022" class="usa-link" aria-describedby="cncr70055-bib-0022">
<sup>22</sup>
</a> In the Spanish cohort, unexposed patients were likewise significantly older, reinforcing the importance of adjusting for baseline imbalances when interpreting these associations.</p>
<p>By contrast, Yilmaz et al.<a href="#cncr70055-bib-0023" class="usa-link" aria-describedby="cncr70055-bib-0023">
<sup>23</sup>
</a> reported a retrospective experience from The MD Anderson Cancer Center on sequential <em>FLT3</em> inhibitor use, which highlighted a progressive decline in response rates with successive <em>FLT3</em> inhibitor treatments. This observation raises the possibility of resistance mechanisms or clonal evolution that may limit the efficacy of subsequent <em>FLT3</em> inhibitor therapies. Interestingly, CR with CRc rates were higher when <em>FLT3</em> inhibitors were combined with other agents compared to monotherapy, suggesting a potential benefit of combination strategies. It is noteworthy, however, that during the period analyzed, gilteritinib was administered as monotherapy in the relapsed/refractory setting (12 patients). The small number of patients treated with gilteritinib in this cohort underscores the need for caution when extrapolating these findings</p>
<p>The poorest outcomes with gilteritinib were observed in patients previously treated with less‐intensive chemotherapy. In this subgroup, 65.8% of patients did not respond, the CR rate was below 10%, and the ORR was 11.4%, resulting in a 1‐year OS probability of just 29%. When compared with the study by Othman et al.,<a href="#cncr70055-bib-0014" class="usa-link" aria-describedby="cncr70055-bib-0014">
<sup>14</sup>
</a> recently published in <em>Blood Advances</em>, our findings appear broadly consistent. In their cohort of 37 patients previously treated with VEN‐AZA, a median OS of 4.5 months was reported, whereas in our cohort of 35 patients treated with less‐intensive chemotherapy, the median OS was 5.9 months. At 12 months, survival rates were 15% and 29% in their and our cohorts, respectively. In both studies, no patients survived beyond 18 months, underscoring the poor prognosis in this population.</p>
<p>Among the 17 patients in our cohort who received VEN‐AZA, we observed a median OS of 7.5 months. Although this appears slightly longer than the median OS reported by Othman et al.,<a href="#cncr70055-bib-0014" class="usa-link" aria-describedby="cncr70055-bib-0014">
<sup>14</sup>
</a> differences in patient characteristics and treatment patterns may account for this variability.</p>
<p>Overall, these findings highlight the limited efficacy of gilteritinib in patients previously exposed to hypomethylating agents (HMA)‐based frontline therapy. However, it is important to recognize that this subgroup represented a particularly high‐risk population compared with the other subgroups in our study. Patients in this cohort had a significantly higher median age (75 vs. 45 years), which is known to correlate with unfavorable disease biology, including a higher prevalence of adverse genetic features and a greater incidence of therapy‐related or secondary AML. These factors, individually and collectively, are well established contributors to reduced treatment responsiveness and likely account for the poorer outcomes observed. Moreover, recent studies have identified molecular alterations such as <em>FLT3</em>‐ITD, <em>NRAS/KRAS</em>, <em>TP53</em>, and <em>BAX</em> mutations as major drivers of resistance to venetoclax and azacitidine, as recently reviewed by Chatzilygeroudi et al.<a href="#cncr70055-bib-0024" class="usa-link" aria-describedby="cncr70055-bib-0024">
<sup>24</sup>
</a> in <em>Cancers</em>. Notably, mutations activating the RAS/MAPK pathway have also emerged as a common and clinically significant mechanism of secondary resistance to gilteritinib.<a href="#cncr70055-bib-0025" class="usa-link" aria-describedby="cncr70055-bib-0025">
<sup>25</sup>
</a>
</p>
<p>Despite these challenges, the use of gilteritinib in relapsed/refractory AML after HMA or HMA plus venetoclax remains appropriate. The drug is approved for this indication, can be administered safely in the outpatient setting, and currently no alternative therapies are available outside of clinical trials.</p>
<p>The patient population included in the present study is not directly comparable to that enrolled in the Admiral trial, and several important differences should be noted. In our cohort, the proportion of patients with primary refractory disease was 27.9%, including 10 individuals who were refractory to two or more courses of intensive chemotherapy, compared with 39.4% in the Admiral study. Moreover, in our analysis, 40% of patients were classified as having an adverse risk according to the ELN classification, whereas only 10% of patients in the Admiral trial had an adverse cytogenetic risk. With regard to prior treatments, the Admiral trial population largely received anthracycline‐based chemotherapy, with only 12.4% previously exposed to a TKI. In contrast, 67.5% of patients in our cohort had received a TKI before gilteritinib. Notably, 35 patients (17%), were refractory to or had relapsed after a less‐intensive regimen consisting of venetoclax and azacitidine and were considered ineligible for transplant. This subgroup experienced the poorest outcomes, with a 1‐year OS of 29%, likely due to a combination of older age (median age, 75 years), a high prevalence of adverse‐risk ELN features (54.3%), and secondary AML (51.4%). Despite differences in baseline characteristics and prior treatment histories, our study demonstrated an ORR (CR + CRi + CRp) of 52.2%, which is comparable to the 60% observed in the Admiral trial, with a similar median OS (10.3 months vs. 9.3 months, respectively).</p>
<p>We acknowledge several limitations of our study. As with any retrospective analysis, there is a potential for selection bias and incomplete data capture. However, the inclusion of consecutive patients from multiple centers helps reduce this risk and enhances the generalizability of our findings. Measurable residual disease (MRD) data were not systematically collected, which limits our ability to evaluate the depth and durability of responses to gilteritinib. Nevertheless, this reflects the reality of clinical practice during the study period, when MRD assessment was not yet widely implemented outside of clinical trials. Additionally, response assessments were determined by treating clinicians rather than through standardized bone marrow evaluations at predefined intervals. Although this may have introduced some variability, it also mirrors real‐world practice, where rigid response monitoring is often not feasible. Despite these constraints, our results provide valuable insights into the use of gilteritinib in routine clinical settings.</p>
<p>To date, seven other real‐world studies on gilteritinib have been published. Notably, patients enrolled in real‐world settings often differ significantly from those in clinical trials, because they are commonly excluded from such trials due to poor performance status or extensive prior treatments. For example, in the observational study by the French AML Intergroup ALFA/FILO,<a href="#cncr70055-bib-0012" class="usa-link" aria-describedby="cncr70055-bib-0012">
<sup>12</sup>
</a> a substantial proportion of patients received gilteritinib in later lines of therapy, with 37.1% treated beyond the second line. Additionally, baseline performance status was considerably poorer, with 83.6% of patients having an Eastern Cooperative Oncology Group (ECOG) score ≥2, compared to only 16.6% in the Admiral trial. Similarly, the Japanese post‐marketing surveillance study reported 23.4% of patients with ECOG ≥2 and 75% with multiple comorbidities, further illustrating that many patients treated in real‐world practice would not meet clinical trial eligibility criteria.<a href="#cncr70055-bib-0009" class="usa-link" aria-describedby="cncr70055-bib-0009">
<sup>9</sup>
</a> In the UK cohort, 36% of patients received at least two prior lines of therapy before starting gilteritinib. Prior treatments included intensive chemotherapy (79%), venetoclax (24%), allogeneic HSCT (19%), and <em>FLT3</em> inhibitors—most commonly midostaurin (41%).<a href="#cncr70055-bib-0014" class="usa-link" aria-describedby="cncr70055-bib-0014">
<sup>14</sup>
</a> Despite these differences in patient populations, clinical outcomes in real‐world studies were broadly consistent with those observed in the Admiral trial, as summarized in Table <a href="#cncr70055-tbl-0004" class="usa-link">4</a>. Composite CR rates ranged from 43.4% in our cohort to 20.5% in the UK study, whereas median overall survival ranged from 11.8 to 6.2 months. Taken together, these real‐world data support the clinical utility of gilteritinib in a broader patient population, including individuals with poor performance status or those who are heavily pretreated—groups typically underrepresented in clinical trials. In conclusion, this real‐world analysis from the Italian EAP demonstrates that patients with relapsed/refractory AML treated with gilteritinib achieved clinical outcomes comparable to those observed in the pivotal Admiral trial. These findings further support the effectiveness of gilteritinib in a more heterogeneous patient population. Further studies are warranted to optimize patient selection, enhance response rates, and improve long‐term outcomes.</p></section><section id="cncr70055-sec-0210"><h2 class="pmc_sec_title">AUTHOR CONTRIBUTIONS</h2>
<p>
<strong>Roberto Cairoli:</strong> Conceptualization, funding acquisition, writing–review and editing, writing–original draft, supervision, investigation, validation, project administration, and data curation. <strong>Lorenzo Del Castello:</strong> Methodology, software, formal analysis, data curation, validation, writing–review and editing, writing–original draft, and investigation. <strong>Silvia Imbergamo:</strong> Investigation and data curation. <strong>Elisabetta Pierdomenico:</strong> Investigation and data curation. <strong>Cristina Papayannidis:</strong> Investigation and data curation. <strong>Erika Borlenghi:</strong> Investigation and data curation. <strong>Calogero Vetro:</strong> Investigation and data curation. <strong>Patrizia Chiusolo:</strong> Investigation and data curation. <strong>Monica Fumagalli:</strong> Investigation and data curation. <strong>Clara Minotti:</strong> Investigation and data curation. <strong>Francesco Marchesi:</strong> Investigation and data curation. <strong>Massimo Bernardi:</strong> Investigation and data curation. <strong>Pellegrino Musto:</strong> Investigation and data curation. <strong>Nicola Fracchiolla:</strong> Investigation and data curation. <strong>Anna Candoni:</strong> Investigation and data curation. <strong>Monia Lunghi:</strong> Investigation and data curation. <strong>Maurizio Musso:</strong> Investigation and data curation. <strong>Fabio Guolo:</strong> Investigation and data curation. <strong>Donato Mannina:</strong> Investigation and data curation. <strong>Albana Lico:</strong> Investigation and data curation. <strong>Anna Maria Scattolin:</strong> Investigation and data curation. <strong>Monica Crugnola:</strong> Investigation and data curation. <strong>Sara Galimberti:</strong> Investigation and data curation. <strong>Gianpaolo Nadali:</strong> Investigation and data curation. <strong>Mauro Turrini:</strong> Investigation and data curation. <strong>Patrizia Zappasodi:</strong> Investigation, <strong>Elisabetta Todisco:</strong> Investigation and data curation. <strong>Claudia Basilico:</strong> Investigation and data curation. <strong>Giovanni Grillo:</strong> Investigation and data curation. <strong>Valentina Mancini:</strong> Investigation and data curation. <strong>Marta Riva:</strong> Investigation and data curation. <strong>Davide Paolo Bernasconi:</strong> Investigation, writing–original draft, writing–review and editing, methodology, validation, software, formal analysis, and data curation. <strong>Rosa Greco:</strong> Investigation, writing–original draft, writing–review and editing, validation, data curation, supervision, conceptualization, and methodology. All authors have read and agreed to the published version of the manuscript.</p></section><section id="cncr70055-sec-0230"><h2 class="pmc_sec_title">CONFLICT OF INTEREST STATEMENT</h2>
<p>Roberto Cairoli reports consulting fees from AbbVie, Janssen Global Services, LLC, and Novartis; and fees for professional activities from Astellas Pharma, Jazz Pharmaceuticals, and Kite Pharma, Inc. Anna Candoni reports consulting fees from Amgen, Jazz Pharmaceuticals, Pfizer, and Servier Pharmaceuticals LLC; and fees for professional activities from AbbVie, Astellas Pharma, and Incyte. Nicola Fracchiolla reports fees for professional activities from AbbVie. Sara Galimberti reports grant and/or contract funding from AbbVie; and fees for travel from Jazz Pharmaceuticals and Novartis. Pellegrino Musto reports fees for professional activities from Novartis. Cristina Papayannidis reports fees for professional activities from AbbVie, Amgen, Astellas Pharma, Blueprint Medicine, Bristol‐Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Menarini International, Otsuka Pharmaceutical, Pfizer, Servier Pharmaceuticals LLC, and Syndax. Mauro Turrini reports honoraria from Johnson &amp; Johnson, Astellas, and ItalFarmaco; fees for travel from Jazz Ph, AstraZeneca, and Johnson &amp; Johnson; fees for professional activities from AstraZeneca and Astellas; and an unpaid role with the Regional Committee on Acute Leukemias. Calogero Vetro reports consulting fees from AbbVie and Jazz Pharmaceuticals. The other authors declare no conflicts of interest.</p></section><section id="sec26"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="cncr70055-sup-0001"><div class="caption p"><p>Supplementary Material</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12369923/bin/CNCR-131-e70055-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">CNCR-131-e70055-s001.docx</a><sup> (620.2KB, docx) </sup>
</div></div></section></section><section id="cncr70055-sec-0220" class="ack"><h2 class="pmc_sec_title">ACKNOWLEDGMENTS</h2>
<p>Fondazione Malattie del Sangue ETS and FD for administrative and data management support. This research was partly funded by Fondazione Malattie del Sangue ETS. The study was conducted in accordance with the Declaration of Helsinki, which ensures ethical consideration for conducting medical research involving human subjects, and approved by the ethical committee of Comitato Etico Milano Area 3 (code no. 628‐27102021, 27 October, 2021). Informed consent was obtained from all subjects involved in the study.</p></section><section id="notes1"><p>

Cairoli R, Del Castello L, Imbergamo S, et al. Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience. Cancer. 2025;e70055. doi: 10.1002/cncr.70055

</p></section><section id="cncr70055-sec-0250"><h2 class="pmc_sec_title">DATA AVAILABILITY STATEMENT</h2>
<p>The data that support the findings of this study are available from the corresponding author on reasonable request.</p></section><section id="cncr70055-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">REFERENCES</h2>
<section id="cncr70055-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="cncr70055-bib-0001">
<span class="label">1.</span><cite>
Nong T, Mehra S, Taylor J. Common driver mutations in AML: biological impact, clinical considerations, and treatment strategies. Cells. 2024;13(16):1392. doi: 10.3390/cells13161392

</cite> [<a href="https://doi.org/10.3390/cells13161392" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11352998/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39195279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=Common%20driver%20mutations%20in%20AML:%20biological%20impact,%20clinical%20considerations,%20and%20treatment%20strategies&amp;author=T%20Nong&amp;author=S%20Mehra&amp;author=J%20Taylor&amp;volume=13&amp;issue=16&amp;publication_year=2024&amp;pages=1392&amp;pmid=39195279&amp;doi=10.3390/cells13161392&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0002">
<span class="label">2.</span><cite>
Padmakumar D, Chandraprabha VR, Gopinath P, et al. A concise review on the molecular genetics of acute myeloid leukemia. Leuk Res. 2021;111:106727. doi: 10.1016/j.leukres.2021.106727

</cite> [<a href="https://doi.org/10.1016/j.leukres.2021.106727" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34700049/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leuk%20Res&amp;title=A%20concise%20review%20on%20the%20molecular%20genetics%20of%20acute%20myeloid%20leukemia&amp;author=D%20Padmakumar&amp;author=VR%20Chandraprabha&amp;author=P%20Gopinath&amp;volume=111&amp;publication_year=2021&amp;pages=106727&amp;pmid=34700049&amp;doi=10.1016/j.leukres.2021.106727&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0003">
<span class="label">3.</span><cite>
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136‐1152. doi: 10.1056/nejmra1406184

</cite> [<a href="https://doi.org/10.1056/nejmra1406184" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26376137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%C2%A0Engl%20J%20Med&amp;title=Acute%20myeloid%20leukemia&amp;author=H%20D%C3%B6hner&amp;author=DJ%20Weisdorf&amp;author=CD%20Bloomfield&amp;volume=373&amp;issue=12&amp;publication_year=2015&amp;pages=1136-1152&amp;pmid=26376137&amp;doi=10.1056/nejmra1406184&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0004">
<span class="label">4.</span><cite>
Negotei C, Colita A, Mitu I, et al. A review of FLT3 kinase inhibitors in AML. J Clin Med. 2023;12(20):6429. doi: 10.3390/jcm12206429

</cite> [<a href="https://doi.org/10.3390/jcm12206429" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10607239/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37892567/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Med&amp;title=A%20review%20of%20FLT3%20kinase%20inhibitors%20in%20AML&amp;author=C%20Negotei&amp;author=A%20Colita&amp;author=I%20Mitu&amp;volume=12&amp;issue=20&amp;publication_year=2023&amp;pages=6429&amp;pmid=37892567&amp;doi=10.3390/jcm12206429&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0005">
<span class="label">5.</span><cite>
Shukla M, Abdul‐Hay M, Choi JH. Molecular features and treatment paradigms of acute myeloid leukemia. Biomedicines. 2024;12(8):1768. doi: 10.3390/biomedicines12081768

</cite> [<a href="https://doi.org/10.3390/biomedicines12081768" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11351617/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39200232/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicines&amp;title=Molecular%20features%20and%20treatment%20paradigms%20of%20acute%20myeloid%20leukemia&amp;author=M%20Shukla&amp;author=M%20Abdul%E2%80%90Hay&amp;author=JH%20Choi&amp;volume=12&amp;issue=8&amp;publication_year=2024&amp;pages=1768&amp;pmid=39200232&amp;doi=10.3390/biomedicines12081768&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0006">
<span class="label">6.</span><cite>
Mori M, Kaneko N, Ueno Y, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3‐mutated acute myeloid leukemia. Invest New Drugs. 2017;35(5):556‐565. doi: 10.1007/s10637-017-0470-z

</cite> [<a href="https://doi.org/10.1007/s10637-017-0470-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5613053/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28516360/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Invest%20New%20Drugs&amp;title=Gilteritinib,%20a%20FLT3/AXL%20inhibitor,%20shows%20antileukemic%20activity%20in%20mouse%20models%20of%20FLT3%E2%80%90mutated%20acute%20myeloid%20leukemia&amp;author=M%20Mori&amp;author=N%20Kaneko&amp;author=Y%20Ueno&amp;volume=35&amp;issue=5&amp;publication_year=2017&amp;pages=556-565&amp;pmid=28516360&amp;doi=10.1007/s10637-017-0470-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0007">
<span class="label">7.</span><cite>
Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first‐in‐human, open‐label, phase 1–2 study. Lancet Oncol. 2017;18(8):1061‐1075. doi: 10.1016/s1470-2045(17)30416-3

</cite> [<a href="https://doi.org/10.1016/s1470-2045(17)30416-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5572576/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28645776/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Selective%20inhibition%20of%20FLT3%20by%20gilteritinib%20in%20relapsed%20or%20refractory%20acute%20myeloid%20leukaemia:%20a%20multicentre,%20first%E2%80%90in%E2%80%90human,%20open%E2%80%90label,%20phase%201%E2%80%932%20study&amp;author=AE%20Perl&amp;author=JK%20Altman&amp;author=J%20Cortes&amp;volume=18&amp;issue=8&amp;publication_year=2017&amp;pages=1061-1075&amp;pmid=28645776&amp;doi=10.1016/s1470-2045(17)30416-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0008">
<span class="label">8.</span><cite>
Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3‐mutated AML. N Engl J Med. 2019;381(18):1728‐1740. doi: 10.1056/nejmoa1902688

</cite> [<a href="https://doi.org/10.1056/nejmoa1902688" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31665578/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Gilteritinib%20or%20chemotherapy%20for%20relapsed%20or%20refractory%20FLT3%E2%80%90mutated%20AML&amp;author=AE%20Perl&amp;author=G%20Martinelli&amp;author=JE%20Cortes&amp;volume=381&amp;issue=18&amp;publication_year=2019&amp;pages=1728-1740&amp;pmid=31665578&amp;doi=10.1056/nejmoa1902688&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0009">
<span class="label">9.</span><cite>
Sugamori H, Lee T, Mitomi T, Yamagishi C. Interim results from a postmarketing surveillance study of patients with FLT3‐mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan. Jpn J Clin Oncol. 2022;52(7):766‐773. doi: 10.1093/jjco/hyac069

</cite> [<a href="https://doi.org/10.1093/jjco/hyac069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9264337/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35523692/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Jpn%20J%20Clin%20Oncol&amp;title=Interim%20results%20from%20a%20postmarketing%20surveillance%20study%20of%20patients%20with%20FLT3%E2%80%90mutated%20relapsed/refractory%20AML%20treated%20with%20the%20FLT3%20inhibitor%20gilteritinib%20in%20Japan&amp;author=H%20Sugamori&amp;author=T%20Lee&amp;author=T%20Mitomi&amp;author=C%20Yamagishi&amp;volume=52&amp;issue=7&amp;publication_year=2022&amp;pages=766-773&amp;pmid=35523692&amp;doi=10.1093/jjco/hyac069&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0010">
<span class="label">10.</span><cite>
Levis M, Perl AE. Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv. 2020;4(6):1178‐1191. doi: 10.1182/bloodadvances.2019000174

</cite> [<a href="https://doi.org/10.1182/bloodadvances.2019000174" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7094008/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32208491/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=Gilteritinib:%20potent%20targeting%20of%20FLT3%20mutations%20in%20AML&amp;author=M%20Levis&amp;author=AE%20Perl&amp;volume=4&amp;issue=6&amp;publication_year=2020&amp;pages=1178-1191&amp;pmid=32208491&amp;doi=10.1182/bloodadvances.2019000174&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0011">
<span class="label">11.</span><cite>
Tzogani K, Roshol H, Olsen HH, et al. The European Medicines Agency review of Gilteritinib (Xospata) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an FLT3 mutation. Oncologist. 2020;25(7):e1070‐e1076. doi: 10.1634/theoncologist.2019-0976

</cite> [<a href="https://doi.org/10.1634/theoncologist.2019-0976" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7356782/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32154636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=The%20European%20Medicines%20Agency%20review%20of%20Gilteritinib%20(Xospata)%20for%20the%20treatment%20of%20adult%20patients%20with%20relapsed%20or%20refractory%20acute%20myeloid%20leukemia%20with%20an%20FLT3%20mutation&amp;author=K%20Tzogani&amp;author=H%20Roshol&amp;author=HH%20Olsen&amp;volume=25&amp;issue=7&amp;publication_year=2020&amp;pages=e1070-e1076&amp;pmid=32154636&amp;doi=10.1634/theoncologist.2019-0976&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0012">
<span class="label">12.</span><cite>
Dumas PY, Raffoux E, Berard E, et al. Gilteritinib activity in refractory or relapsed FLT3‐mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. Leukemia. 2023;37(1):91‐101. doi: 10.1038/s41375-022-01742-7

</cite> [<a href="https://doi.org/10.1038/s41375-022-01742-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36376378/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Gilteritinib%20activity%20in%20refractory%20or%20relapsed%20FLT3%E2%80%90mutated%20acute%20myeloid%20leukemia%20patients%20previously%20treated%20by%20intensive%20chemotherapy%20and%20midostaurin:%20a%20study%20from%20the%20French%20AML%20Intergroup%20ALFA/FILO&amp;author=PY%20Dumas&amp;author=E%20Raffoux&amp;author=E%20Berard&amp;volume=37&amp;issue=1&amp;publication_year=2023&amp;pages=91-101&amp;pmid=36376378&amp;doi=10.1038/s41375-022-01742-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0013">
<span class="label">13.</span><cite>
Numan Y, Abdel Rahman Z, Grenet J, et al. Gilteritinib clinical activity in relapsed/refractory FLT3‐mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022;97(3):322‐328. doi: 10.1002/ajh.26447

</cite> [<a href="https://doi.org/10.1002/ajh.26447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34981560/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Hematol&amp;title=Gilteritinib%20clinical%20activity%20in%20relapsed/refractory%20FLT3%E2%80%90mutated%20acute%20myeloid%20leukemia%20previously%20treated%20with%20FLT3%20inhibitors&amp;author=Y%20Numan&amp;author=Z%20Abdel%20Rahman&amp;author=J%20Grenet&amp;volume=97&amp;issue=3&amp;publication_year=2022&amp;pages=322-328&amp;pmid=34981560&amp;doi=10.1002/ajh.26447&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0014">
<span class="label">14.</span><cite>
Othman J, Hwang A, Brodermann M, et al. Outcomes with single‐agent gilteritinib for relapsed or refractory FLT3‐mutant AML after contemporary induction therapy. Blood Adv. 2024;8(21):5590‐5597. doi: 10.1182/bloodadvances.2024014017

</cite> [<a href="https://doi.org/10.1182/bloodadvances.2024014017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11541456/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39265176/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=Outcomes%20with%20single%E2%80%90agent%20gilteritinib%20for%20relapsed%20or%20refractory%20FLT3%E2%80%90mutant%20AML%20after%20contemporary%20induction%20therapy&amp;author=J%20Othman&amp;author=A%20Hwang&amp;author=M%20Brodermann&amp;volume=8&amp;issue=21&amp;publication_year=2024&amp;pages=5590-5597&amp;pmid=39265176&amp;doi=10.1182/bloodadvances.2024014017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0015">
<span class="label">15.</span><cite>
Shimony S, Canaani J, Kugler E, et al. Gilteritinib monotherapy for relapsed/refractory FLT3‐mutated acute myeloid leukemia: a real‐world, multi‐center, matched analysis. Ann Hematol. 2022;101(9):2001‐2010. doi: 10.1007/s00277-022-04895-8

</cite> [<a href="https://doi.org/10.1007/s00277-022-04895-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35739428/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Hematol&amp;title=Gilteritinib%20monotherapy%20for%20relapsed/refractory%20FLT3%E2%80%90mutated%20acute%20myeloid%20leukemia:%20a%20real%E2%80%90world,%20multi%E2%80%90center,%20matched%20analysis&amp;author=S%20Shimony&amp;author=J%20Canaani&amp;author=E%20Kugler&amp;volume=101&amp;issue=9&amp;publication_year=2022&amp;pages=2001-2010&amp;pmid=35739428&amp;doi=10.1007/s00277-022-04895-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0016">
<span class="label">16.</span><cite>
Kunadt D, Zukunft S, Röllig C, et al. Gilteritinib and allogeneic hematopoietic stem cell transplantation improve outcome in relapsed/refractory FLT3‐mutated acute myeloid leukemia patients: real‐world data from a multicenter analysis. Paper presented at: 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT); 2023; OS01‐01.</cite>
</li>
<li id="cncr70055-bib-0017">
<span class="label">17.</span><cite>
Dogu MH, Tekgunduz AIE, Deveci B, et al. Gilteritinib (XOSPATA) in Turkey: early access program results. Mediterr J Hematol Infect Dis. 2023;15(1):e2023031. doi: 10.4084/mjhid.2023.031

</cite> [<a href="https://doi.org/10.4084/mjhid.2023.031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10171205/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37180209/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mediterr%20J%20Hematol%20Infect%20Dis&amp;title=Gilteritinib%20(XOSPATA)%20in%20Turkey:%20early%20access%20program%20results&amp;author=MH%20Dogu&amp;author=AIE%20Tekgunduz&amp;author=B%20Deveci&amp;volume=15&amp;issue=1&amp;publication_year=2023&amp;pages=e2023031&amp;pmid=37180209&amp;doi=10.4084/mjhid.2023.031&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0018">
<span class="label">18.</span><cite>
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377. doi: 10.1182/blood.2022016867

</cite> [<a href="https://doi.org/10.1182/blood.2022016867" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35797463/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Diagnosis%20and%20management%20of%20AML%20in%20adults:%202022%20recommendations%20from%20an%20international%20expert%20panel%20on%20behalf%20of%20the%20ELN&amp;author=H%20D%C3%B6hner&amp;author=AH%20Wei&amp;author=FR%20Appelbaum&amp;volume=140&amp;issue=12&amp;publication_year=2022&amp;pages=1345-1377&amp;pmid=35797463&amp;doi=10.1182/blood.2022016867&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0019">
<span class="label">19.</span><cite>
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424‐447. doi: 10.1182/blood-2016-08-733196

</cite> [<a href="https://doi.org/10.1182/blood-2016-08-733196" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5291965/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27895058/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Diagnosis%20and%20management%20of%20AML%20in%20adults:%202017%20ELN%20recommendations%20from%20an%20international%20expert%20panel&amp;author=H%20D%C3%B6hner&amp;author=E%20Estey&amp;author=D%20Grimwade&amp;volume=129&amp;issue=4&amp;publication_year=2017&amp;pages=424-447&amp;pmid=27895058&amp;doi=10.1182/blood-2016-08-733196&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0020">
<span class="label">20.</span><cite>
Ferrara F, Barosi G, Venditti A, et al. Consensus‐based definition of unfitness to intensive and nonintensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision Making. Leukemia. 2013;27(5):997‐999. doi: 10.1038/leu.2012.303

</cite> [<a href="https://doi.org/10.1038/leu.2012.303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23653072/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Consensus%E2%80%90based%20definition%20of%20unfitness%20to%20intensive%20and%20nonintensive%20chemotherapy%20in%20acute%20myeloid%20leukemia:%20a%20project%20of%20SIE,%20SIES%20and%20GITMO%20group%20on%20a%20new%20tool%20for%20therapy%20decision%20Making&amp;author=F%20Ferrara&amp;author=G%20Barosi&amp;author=A%20Venditti&amp;volume=27&amp;issue=5&amp;publication_year=2013&amp;pages=997-999&amp;pmid=23653072&amp;doi=10.1038/leu.2012.303&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0021">
<span class="label">21.</span><cite>
Pagliuca S, Schmid C, Santoro N, et al. Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024;11(6):e448‐e458. doi: 10.1016/s2352-3026(24)00098-x

</cite> [<a href="https://doi.org/10.1016/s2352-3026(24)00098-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38796194/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Haematol&amp;title=Donor%20lymphocyte%20infusion%20after%20allogeneic%20haematopoietic%20cell%20transplantation%20for%20haematological%20malignancies:%20basic%20considerations%20and%20best%20practice%20recommendations%20from%20the%20EBMT&amp;author=S%20Pagliuca&amp;author=C%20Schmid&amp;author=N%20Santoro&amp;volume=11&amp;issue=6&amp;publication_year=2024&amp;pages=e448-e458&amp;pmid=38796194&amp;doi=10.1016/s2352-3026(24)00098-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0022">
<span class="label">22.</span><cite>
Vives S, Quintela D, Morgades M, et al. Salvage therapy with second‐generation inhibitors for FLT3 mutated acute myeloid leukemia: a real‐world study by the CETLAM and PETHEMA groups. Cancers. 2024;16(23):4028. doi: 10.3390/cancers16234028

</cite> [<a href="https://doi.org/10.3390/cancers16234028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11639769/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39682214/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Salvage%20therapy%20with%20second%E2%80%90generation%20inhibitors%20for%20FLT3%20mutated%20acute%20myeloid%20leukemia:%20a%20real%E2%80%90world%20study%20by%20the%20CETLAM%20and%20PETHEMA%20groups&amp;author=S%20Vives&amp;author=D%20Quintela&amp;author=M%20Morgades&amp;volume=16&amp;issue=23&amp;publication_year=2024&amp;pages=4028&amp;pmid=39682214&amp;doi=10.3390/cancers16234028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0023">
<span class="label">23.</span><cite>
Yilmaz M, Alfayez M, DiNardo C, et al. Outcomes with sequential FLT3‐inhibitor‐based therapies in patients with AML. J Hematol Oncol. 2020;13(1):132. doi: 10.1186/s13045-020-00964-5

</cite> [<a href="https://doi.org/10.1186/s13045-020-00964-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7542942/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33032648/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hematol%20Oncol&amp;title=Outcomes%20with%20sequential%20FLT3%E2%80%90inhibitor%E2%80%90based%20therapies%20in%20patients%20with%20AML&amp;author=M%20Yilmaz&amp;author=M%20Alfayez&amp;author=C%20DiNardo&amp;volume=13&amp;issue=1&amp;publication_year=2020&amp;pages=132&amp;pmid=33032648&amp;doi=10.1186/s13045-020-00964-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0024">
<span class="label">24.</span><cite>
Chatzilygeroudi T, Karantanos T, Pappa V. Unraveling venetoclax resistance: navigating the future of HMA/venetoclax‐refractory AML in the molecular era. Cancers.2025;17(9):1586. doi: 10.3390/cancers17091586

</cite> [<a href="https://doi.org/10.3390/cancers17091586" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12071220/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40361510/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Unraveling%20venetoclax%20resistance:%20navigating%20the%20future%20of%20HMA/venetoclax%E2%80%90refractory%20AML%20in%20the%20molecular%20era&amp;author=T%20Chatzilygeroudi&amp;author=T%20Karantanos&amp;author=V%20Pappa&amp;volume=17&amp;issue=9&amp;publication_year=2025&amp;pages=1586&amp;pmid=40361510&amp;doi=10.3390/cancers17091586&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70055-bib-0025">
<span class="label">25.</span><cite>
McMahon CM, Ferng T, Canaani J, et al. Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective <em>FLT3</em> inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050‐1063. doi: 10.1158/2159-8290.cd-18-1453

</cite> [<a href="https://doi.org/10.1158/2159-8290.cd-18-1453" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11994087/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31088841/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=Clonal%20selection%20with%20Ras%20pathway%20activation%20mediates%20secondary%20clinical%20resistance%20to%20selective%20FLT3%20inhibition%20in%20acute%20myeloid%20leukemia&amp;author=CM%20McMahon&amp;author=T%20Ferng&amp;author=J%20Canaani&amp;volume=9&amp;issue=8&amp;publication_year=2019&amp;pages=1050-1063&amp;pmid=31088841&amp;doi=10.1158/2159-8290.cd-18-1453&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>Supplementary Material</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12369923/bin/CNCR-131-e70055-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">CNCR-131-e70055-s001.docx</a><sup> (620.2KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that support the findings of this study are available from the corresponding author on reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cancer are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/cncr.70055"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/CNCR-131-e70055.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (528.0 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12369923/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12369923/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12369923%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369923/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12369923/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12369923/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40839405/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12369923/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40839405/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12369923/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12369923/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="aJPs7aCWt2Bo07kZ8jlB5vSnbbXJLzdFj8fmywfUZNYgnCwLzGCYH5sFsV9uogzu">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
